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The prevalence of neurological/neurodegenerative diseases, such as
Alzheimer’s disease is known to be increasing due to an aging population and
is anticipated to further grow in the decades ahead. The treatment of brain
diseases is challenging partly due to the inaccessibility of therapeutic agents
to the brain. An increasingly important observation is that the physiology of
the brain alters during many brain diseases, and aging adds even more to the
complexity of the disease. There is a notion that the permeability of the
blood–brain barrier (BBB) increases with aging or disease, however, the body
has a defense mechanism that still retains the separation of the brain from
harmful chemicals in the blood. This makes drug delivery to the diseased
brain, even more challenging and complex task. Here, the physiological
changes to the diseased brain and aged brain are covered in the context of
drug delivery to the brain using nanoparticles. Also, recent and novel
approaches are discussed for the delivery of therapeutic agents to the
diseased brain using nanoparticle based or magnetic resonance imaging
guided systems. Furthermore, the complement activation, toxicity, and
immunogenicity of brain targeting nanoparticles as well as novel in vitro BBB
models are discussed.
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1. Introduction
Despite many advances both in understand-
ing and technology, the reliable delivery
of treatments to the brain is an unsolved
challenge. Nanoparticles (NPs) have gained
much recent prominence as a potential tool
to achieve this valuable aim.[1–3] As research
in this area has expanded, several of the is-
sues that might increase the likelihood of
success or prevent creation of a new therapy
have become clearer. In this review, we seek
to describe the biological, physiological, and
physical background to some of these with
the intention of encouraging those working
in this area at the same time as providing
them with a map that highlights some of the
pitfalls that must be avoided.
In terms of opportunities, the latest find-
ings in normal, aged, and diseased brains
reveal that in certain disease states and
upon aging, changes take place in the
blood–brain barrier (BBB) permeability[4–11]
that could improve the ability of NPs to
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access the brain.[12] These changes impose restrictions on the
NPs or nanocarriers (NCs) that differ from those required to
access the brain when it is in a normal, healthy state. As a re-
sult, researchers have investigated methods to maintain or re-
cover the BBB functionality such as the intravenous (i.v.) injec-
tion of mesenchymal stem cells (to inhibit the deterioration of
BBB function),[7] oral administration of terflunomide (promot-
ing pericyte coverage, pericyte survival and downregulating tight
junction degradation),[8] or use of Panax notoginseng saponins
(by activation of Nrf2 antioxidant defense system).[13] These ap-
proaches could improve the efficacy of drug delivery to the brain
by NPs or NCs by restoring the BBB integrity. Furthermore, the
receptors involved in the normal functioning of the BBB may
be dysfunctional in brain diseases.[14,15] Finally, the physiologi-
cal environment of the brain may change due to chemicals or
diseases.[16–18]
In this review article, the details of the healthy state are first
described and then the variations in a variety of states of dis-
ease, damage or aging. Technological innovations have provided
researchers with new tools to study the BBB and these are begin-
ning to also include variations that reflect the changes in the BBB
in disease states but gaps are highlighted by our comprehensive
survey such as models for the aging BBB.
In terms of challenges, NPs have been found to have a par-
ticular ability to provoke complement activation that can lead
to severe immune responses; this too is dependent upon the
characteristics of the NPs.[19–21] The ability of NPs to cause
cytotoxicity[22] via either apoptosis[23,24] or necrosis[25] are ex-
plored as are further aspects of immunogenicity,[26] hemolytic
properties[27] and more general toxicity.
Throughout the review, detailed tables provide information
about the behavior of a variety of NPs of different composition
and morphology that highlight the breadth of research in this
area and provide design guidelines that will enable studies to fo-
cus on NPs with an increased likelihood of becoming part of new
therapeutic modalities.
2. Physiological Barriers to the Brain Parenchyma
There are five barriers between the brain and peripheral tissues
in adults:[28]
• The BBB, at the capillaries of the brain parenchyma
• The arachnoid barrier at the meninges
• The blood cerebrospinal fluid (CSF) barrier covered by the ep-
ithelial cells at the choroid plexus
• The circumventricular organs (CVOs) barrier formed by tight
junctions between adjacent tanycytes
• The glia limitans interface between the CSF and the brain
parenchyma.
These are explained in the following.
2.1. Blood–Brain Barrier
The BBB maintains a homeostasis within the brain environ-
ment, which is essential to the normal functions of neurons in
Figure 1. TEM image of healthy human neurovascular unit in the brain.
Reproduced with permission.[30] Copyright 2011, IntechOpen. (P: pericyte,
BL: basal lamina, EC: endothelial cell, A: astrocyte, TJ: tight junction.
the brain. The BBB achieves this partly by shielding the neu-
ral cells from harmful agents in the blood, but this protective
role of the BBB makes drug delivery to the brain more chal-
lenging compared to other organs, where blood capillary fen-
estration facilitates delivery of the drug molecules to the target
cells. To overcome the BBB, NPs and NCs have been developed,
which cross the BBB by mechanisms such as receptor mediated
transcytosis (RMT), a process inherent to normal functioning
brain endothelial cells.[1–3] Figure 1 presents a transmission elec-
tron microscopy (TEM) image of a normal human neurovascular
unit. The tight junction (TJ) is presented as an electron-dense
elongated line, with the basal lamina (BL) encompassing an en-
dothelial cell (EC), surrounded by pericytes, but with gaps in the
BL, with astrocyte end-feet located behind. Neuropils can also
be identified. The central nervous system (CNS) contains both
micro- and macrovessels. These occupy 25–30% of the total brain
volume. The total surface area of microvasculature is 12 m2 in the
adult brain, which corresponds to ≈100 cm2 g−1 of brain tissue.
The total length of capillaries in the brain is about 650 km. These
capillaries are typically 40 µm apart and the capillary lumen di-
ameter is about 6 µm. TJs are formed between two overlapping
separate impermeable cell membranes, one on the inside of the
vessel wall (luminal side) and the other on the outside (abluminal
side). Hence, the TJ is a slant cut rather than a straight short cut
from the luminal side to the abluminal side. Typically the gap is
between 300 and 500 nm between the luminal side and ablumi-
nal side of brain microvessels.[29]
In the young rat brain, the thickness of the basal lamina (also
known as basement membrane, BM) is 50 nm in the frontal cor-
tex and 49 nm in the hippocampus CA1 region.[31] The BL is
composed of three layers. Layer one, produced by EC, contains
laminin-8[32] and laminin-10.[32,33] The middle layer contains
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Figure 2. Schematic presentation of basal lamina (BL) in the neural vascular unit (NVU). This diagram presents a protein network within the BL, which
affects the diffusion of NCs that cross the BBB toward brain parenchyma, with smaller NCs being more efficient in crossing the network compared to
larger NCs, which may be trapped in the protein network.
collagen IV,[34,35] agrin,[36] elastin by pericytes,[37] perlecan,[38,39]
and fibronectin.[34,35] Layer three contributed by astrocytes con-
tains laminin-1 and laminin-2.[32] Nidogen-1 is spread within the
BL and links collagen IV to laminin to form a 3D matrix (Fig-
ure 2),[40] lack of nidogen-1 results in discontinuation of BL in
the brain capillaries.[41] This complexity of BL further restricts the
mobility of NPs in the brain, in particular larger NCs (>100 nm)
(Figure 2).[42] However, it should be noted that the NP size is not
the only factor that can block the NP in the BL.[43] Adsorption
of proteins and surface charge of NPs could play major roles in
slowing the NPs diffusing through the BL.[43] This could reduce
the relocation of the NP within the brain parenchyma, as the BL
is continued to the extracellular matrix (ECM).[44]
Pericytes are completely embedded within the BL. Laminin 8
(containing 𝛼4 chain) facilitates transmigration of T-cells from
the blood into the BL under inflammatory conditions.[32] Ac-
tivated T-cells interact with intercellular adhesion molecule 1
on the surface of ECs and can induce a transient breakdown
of the barrier.[45] Further dislocation of T-cells into the neural
tissue depends on the permission of local macrophages. Lo-
cal macrophages and ECs will release matrix metalloproteinases
(MMP), if relocation of T-cells is needed to digest ECM and make
a path for T-cells.[46,47] Previous studies have shown immune re-
actions in the brain toward NPs. Therefore, the BL could be the
site where NCs are identified as foreign bodies in the brain and
cytokines are released.
2.2. The Arachnoid Barrier at the Meninges
Figure 3 presents a schematic diagram of the meninges. The dura
mater is about 1 mm thick in the human brain, and it is com-
posed of dense fibrous tissue. Microscopically, the dura consists
of densely packed bundles of collagen fibers with interspersed
arteries, veins, and lymphatics.[28] The dura mater lymphatic
vessels contribute to the clearance of macromolecules from the
brain.[48] The blood vessels are fenestrated in the dura mater.[49]
It may be, therefore suggested that NCs may leave blood vessels
via the fenestrated blood vessels in the dura mater.
This could be an explanation for the weak appearance of non-
targeted NPs in the brain as observed in previous studies.[50]
The arachnoid covers the inner aspect of the dura mater and
forms the arachnoid blood-CSF barrier, separating the CSF in the
subarachnoid space (SAS) from fenestrated blood vessels in the
dura mater. In humans, the arachnoid barrier is 200 µm thick,
and the main body of the arachnoid is composed of closely packed
leptomeningeal cells joined by desmosomes and devoid of base-
ment membranes. On the other hand, the arachnoid cells adja-
cent to the dura are joined by TJs, which prevent solutes or cells
gaining access to the SAS or conversely solutes from the SAS to
the dura mater.
However, a recent study suggests that drug molecules exiting
the fenestrated blood vessels in the dura mater may be trans-
ported to the CSF in the SAS by transporters on the arach-
noid barrier.[51] Similarly, the drug molecules may be transported
from the CSF in the SAS back to the dura mater and then into
blood capillaries. Two key transporters have been identified in
the arachnoid barrier of mouse: 1) P-glycoprotein (P-gp), and 2)
breast cancer resistance protein (BCRP).[51] BCRP and P-gp are
also highly expressed in human arachnoid tissue.[51] Sheet-like
and filiform trabeculae with cores of collagen fibers coated by
leptomeningeal cells extend from the arachnoid barrier across
the human SAS to join the pia on the surface of the brain
parenchyma (subarachnoid space plus CSF depicted in Figure 3).
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Figure 3. A schematic diagram of arachnoid barrier at the meninges. This diagram shows that NPs may exit the fenestrated blood vessels in the dura
mater. It also shows that CSF in the subarachnoid space (SAS) enters the brain parenchyma via the paravascular space and interstitial fluid ISF exits
the brain parenchyma along the BL and mixes with CSF in the SAS. The arachnoid barrier separates the dura mater from the SAS, and the pia mater
separates brain parenchyma from the SAS. Glia limitans and astrocytes form a barrier between the pia mater and the brain parenchyma. The subpia
mater is mainly composed of collagen fibers.
Trabeculae divides the SAS into compartments with sus-
pended arteries and veins within the SAS.[52] As shown in Fig-
ure 3, there are major arteries in the SAS, which branch per-
pendicularly into the brain parenchyma.[53] In humans, the pia
mater is composed of a thin layer of leptomeningeal cells that are
joined by gap junctions.[54] The pia mater is closer to the astro-
cytes (glia limitans) but it is separated from these by the subpia
mater, which contains blood vessels and collagen.[28,55] The pia
mater covers the surface of arteries and veins that leave the SAS,
cross the subpia mater and enter the brain parenchyma.[55] Fig-
ure 3 also presents the flow of CSF from the SAS into the paravas-
cular space,[56] and the reverse flow of interstitial fluid (ISF) along
the BM in the tunica media of cerebral arteries that form the in-
tramural peri-arterial drainage (IPAD).[57] When 15 nm gold NPs
were injected into mouse CSF, the NPs appeared in the basement
layer of cortical arteries. This shows that cerebral vascular base-
ment membranes form the pathways for fluid passing into and
out of the brain.[58] Thus tracers or drug molecules present in
the CSF will enter the brain alongside arteries and leave the brain
back to the CSF, but along separated periarterial BM pathways.[57]
Alternatively, if NCs in the brain parenchyma release their cargo,
the drug molecules will enter the CSF via the convective ISF flow
and re-enter the brain parenchyma via the CSF flow into the par-
avascular space.
2.3. The Blood CSF Barrier at the Choroid Plexus
A schematic diagram of the choroid plexus in the brain is pre-
sented in Figure 4. The choroid plexus is a highly vascularized
tissue with numerous villi on the surface; it is located within each
ventricle of the brain. The choroid plexus is separated from the
CSF by single-layered epithelium cells, and brain parenchyma
are separated from the CSF in the ventricles by ependymal cells.
The capillaries in the choroid plexus are separated from the ep-
ithelial cells by a thin layer of connective tissue called stroma.
Bundles of collagen are present in the stroma of the choroid
plexus, but they are surrounded by leptomeningeal cells. In older
humans, there are spheres of collagen fibers, produced and sur-
rounded by leptomeningeal cell. However, these may become cal-
cified to form calcospherites in the stroma of the choroid plexus
(called psammoma bodies).[59–61]
The epithelium cells in the choroid plexus form TJs, how-
ever, the electrical resistance (200 Ω cm2)[62] is estimated to be
much less than the BBB (1870 Ω cm2).[63] This implies that the
choroid plexus epithelium membrane is leaky.[64] The choroid
plexus has been suggested to be a site for entry of pathogens into
the brain tissue.[65] Pathogens may enter through the transcellu-
lar or paracellular routes of epithelial cells in the choroid plexus,
or in infected phagocytes via the “Trojan-horse” mechanism.[66]
Figure 4 also presents schematically the potential dislocation of
NPs from the perforated blood vessels in the choroid plexus into
the stroma.[67,68] Most likely, the NPs will remain in the stroma
due to the TJs at the epithelial cells of the choroid plexus,[69]
however, they may enter into the brain tissue via the Trojan-
horse mechanism.[70] It should be noted that epithelial cells in
the choroid plexus may uptake NPs;[68] and the epithelial cells of
the choroid plexus may transport NCs into the CSF via RMT.[71]
The choroid plexus could also be a another point of entry
for NPs to the brain, when the surface of NPs is decorated
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Figure 4. A schematic diagram of choroid plexus in the brain. Choroid plexus is a highly vascularized tissue with fenestrated blood vessels which provides
the opportunity for small NCs to exit the blood vessels and enter the tissue of the choroid plexus (stroma). The choroid plexus is located within each
ventricle of the brain, and it is separated from the CSF in the ventricles by epithelial cells, which have numerous villi on the surface. As a consequence of
aging, calcified bodies are formed within the stroma called psammoma bodies. Brain parenchyma is separated from the CSF by ependymal cells. Also,
white blood cells (myeloid cells) exit the blood vessels in the choroid plexus and occupy the stroma.
with a hybrid ligand (e.g., combination of transferrin receptor
(TfR) and cohesin domain from Clostridium thermocellum).[71] In
another study, uncoated poly(butyl cyanoacrylate) (PBCA) NPs
(185–200 nm) managed to accumulate in the brain at concen-
trations below 1% of the dose after i.v. administration in Wis-
tar Unilever rats.[72] Although this is not considerable, the NPs
might have been accumulated in the choroid plexus and partly en-
tered the brain via the Trojan-horse mechanism using immune
cells. Coating these PBCA NPs with polysorbate 80 (Tween 80)
doubled the amounts of NPs accumulated in the brain.[72] More-
over, uptake of untargeted-albumin NPs (208 nm) by the BBB
ECs has been observed, but these particles were not seen in the
brain parenchyma after i.v. injection into SV 129 mice.[73]
On the other hand, apolipoprotein E (ApoE) coated albumin
NPs (249 nm) were found in all brain regions and neurons.[73] It
is unlikely that ApoE NPs would be able to access all the brain
regions solely by crossing the BBB, due to their large sizes. Most
likely, they also crossed epithelium cells of the choroid plexus,[74]
which led to the distribution of NPs in other regions of the brain
via the CSF.
Hence, the size and surface decoration of NCs play important
roles in targeting different regions of the brain.
2.4. Circumventricular Organs Barrier
CVOs are highly vascularized brain structures with fenestrated
blood vessels and neurons. CVOs permit sensing of hormones
in the blood and the release of hormones to the blood. These
structures allow the brain to monitor the blood without com-
promising the BBB. There are three sensory CVOs: the subfor-
nical organ, the organum vasculosum of the lamina terminalis,
and the area postrema. These CVOs permit neurons to sense the
blood, and relay related information to other regions of the brain.
Also, there are four secretory CVOs: the neurohypophysis, the
median eminence (ME), the intermediate lobe of pituitary gland,
and the pineal gland.[75] The subcommisural organ is an indis-
criminate CVO, which means that some classify it as a CVO,[76]
whereas other do not.[75] Indeed, one reason that it might not
be considered as a CVO is because this organ lacks fenestrated
capillaries.[77]
Ependymal cells border CVOs. These form the lining of both
ventricles and the brain parenchyma side, which is bordered
by astroglial cells.[78] All three TJ proteins, ZO-1, occludin and
claudin1, appeared at the lining of ventricles of mouse brain,[78]
with occludin and ZO-1 appearing on the brain parenchyma
side.[79] These proteins create a barrier around CVOs such that
staining molecules for example Evans blue (MW = 960.81 Da)
remain within CVOs following i.v. injection.[78,79]
A schematic diagram of the ME is illustrated in Figure 5. This
figure shows three types of ependymal cells: the ventral part,
the arcuate nucleus of the hypothalamus (ARH), and the bor-
der (the bottom part). Figure 5 shows occludin and ZO-1 at the
ARH ependymal cells, all three TJ proteins (ZO-1, occludin, and
claudin1) at the ventral side, and claudin 1 at the border side.
The ME contains rich fenestrated capillaries, which could al-
low translocation of NCs from the blood vessels into the CVOs.
This is also shown schematically in Figure 5. Experimental ev-
idence suggests that the ependymal cells (at the ventral border)
can transport macromolecules such as leptin[80] into the blood via
transcytosis from the CSF[81] and vice versa.
Therefore, if NCs release drug molecules, they may be trans-
ported across the ependymal cells into the CSF (shown schemat-
ically in Figure 5).
2.5. Glia Limitans
The glia limitans is a CNS barrier formed by astrocyte end-
feet that protects the brain parenchyma. Figure 6 presents a
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Figure 5. Schematic diagram of the median eminence (ME), one of the circumventricular organs (CVOs). This diagram shows three types of ependymal
cells: the ventral part (also called HPZ cells), the arcuate nucleus of the hypothalamus (ARH), and the border (the bottom part). This figure shows
occludin and ZO-1 at the ARH ependymal cells, all three TJ proteins (ZO-1, occluding, and claudin1) at the ventral side, and claudin 1 at the border side.
The ME contains rich fenestrated capillaries, which could allow dislocation of NCs from the blood vessels into the CVOs. The tanycytes with their TJ
proteins prevent diffusion of NCs to the brain parenchyma. However, the drug molecules released from NCs may enter the CSF in the ventricle by the
transporter/receptors at the HPZ cells.
Figure 6. Schematic presentation of the glia limitans interface between the CSF and the brain parenchyma and the circulation of the CSF in the brain.
This diagram presents injection of NCs/NPs with two sizes into the CSF large and small. Large NCs/NPs will circulate within the brain as well as the
small NCs/NPs but will not cross the glia limitans, while small NCs/NPs will cross the glia limitans and penetrate into the brain parenchyma. This figure
also shows that NCs/NPs will start their journeys from the ventricle (site of injection) and via the CSF will flow into the SAS, and then into the brain
through the perivascular space along the arteries. After transporting along the BL and along the walls of veins, the NCs/NPs will return into the SAS.
Due to the size of NCs/NPs (both large and small sizes), they will not be able to leave the CSF via the arachnoid villus into the dural venous sinus, which
joins the systemic circulation.
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schematic diagram of the glia limitans barrier in the brain. Glia
limitans forms around blood vessels, hence NPs or inflamma-
tory cells that cross the BBB will face this barrier. Glia limitans
also forms beneath the pia mater, and hence protects the brain
from inflammatory cells or NPs in the CSF. It should be noted
that glia limitans is permissive to molecules in a size depen-
dent manner. Tracers with molecular weights less than 2000 kDa
managed to cross the glia limitans, and molecules with sizes
of 759 Da easily crossed the glia limitans and were distributed
widely in the brain parenchyma following injections into the cis-
terna magna.[56] Therefore, glia limitans acts like a sieve to pro-
tect the brain parenchyma from harmful molecules. In addition,
IgG molecules (≈10 nm in size) could not cross the glia limitans
following injection into the cisterna magna.[82]
On the other hand, NPs with a size of 24 nm crossed the glia
limitans following convection-enhanced delivery to the cortex of
rats.[83] This technique involves the infusion of NP solution into
the brain parenchyma, with transport of NPs into the brain in-
terstitium being driven by a pressure gradient. However, 100 nm
NPs remained in the arteriol perivascular space, and could not
cross the glia limitans even by applying this technique.[83]
These studies suggest that NCs should have sizes in the range
of 10–24 nm to cross the glia limitans and penetrate into the brain
parenchyma following crossing the BBB or after intrathecal injec-
tion. It should be added that larger NPs may manage to cross the
glia limitans, if the surface of the NPs is decorated with appropri-
ate targeting ligands. For example, as explained above, albumin
NPs decorated with ApoE entered neurons following i.v. injection
into mice.[73] The NPs had an average diameter of 249 nm. How-
ever, the number of these NPs in the neurons was scarce, suggest-
ing the prevention of NP transport into the brain parenchyma by
the glia limitans. By referring to the use of exosomes in drug de-
livery to the brain,[84] it may be accepted that the NPs/NCs should
have surface decoration with brain targeting ligands and sizes
preferably less than 80 nm, or ideally around 24 nm. To further
support this claim, adeno associated viruses (AAVs, 20–25 nm)
have been considered for delivery for DNA to the brain following
i.v. injection.[85–87]
The CSF is produced mainly by the choroid plexus, and this
is schematically shown in Figure 6. The rate of right lateral ven-
tricular CSF formation was determined in the range of 0.0622
to 0.103 mL min−1,[88] while another work found that the rate
of CSF formation was in the range of 0.083 to 0.103 mL min−1
in three adult patients (two with meningeal cancer and one with
dementia).[89] CSF flows from the choroid plexus to the SAS and
part of it enters the brain via the paravascular space surrounding
the descending arterioles to the brain. CSF circulates back to the
SAS via the perivascular space around the cerebral veins. Part of
the CSF leaves the SAS toward dural venous sinus through the
arachnoid villus.
Figure 6 also presents distribution of large (100 nm) and small
(24 nm) NCs in the brain following intrathecal injection. The ba-
sis for these choices is according to previous investigations. The
crossing of 24 nm NPs through the glia limitans has been shown,
but 100 nm NPs remain within the perivascular space.[83] This
figure presents that small NCs would cross the glia limitans and
enter the brain parenchyma, but larger NPs will be circulating
in the CSF. These NPs will not be able to leave the CSF via the
arachnoid villus, nor crossing the arachnoid barrier and entering
dura mater unless they can be transported back to the blood by
transcytosis via the transporters in the arachnoid barrier or the
BBB, or taken up by macrophages in the brain.
A schematic depiction of the glymphatic pathway is shown in
Figure 7. CSF enters the brain through the paravascular paths,
crosses the glia limitans, sweeps the brain parenchyma, mixes
with ISF, leaves brain parenchyma through the opposite-side glia
limitans, and is cleared from the brain via paravenous paths. In
this diagram, NPs are shown with two different sizes (small and
large). Large NPs (100–200 nm) will remain within the arteriole
paravascular path, while small NPs (24 nm) will cross the glia
limitans and reach the brain parenchyma. The small NPs would
leave the brain by following the convective flow of ISF. As ex-
plained in the previous sections, the relocation of NPs in brain
parenchyma is not only size dependent. The interaction of NPs
with extracellular matrix, and surfaces of the cells will affect their
distribution in the brain.
Figure 7 also presents that large NCs may release their pay-
load in the BM due to degradation by enzymes such as MMP-9.
Hence, the payload may be transported to the brain parenchyma
by the convective flow of CSF to the brain parenchyma. It is also
suggested that ISF flows in the opposite direction to the CSF to-
ward arteriole paravascular space and eventually into the CSF in
the SAS.[28] Therefore, part of the released cargo might be trans-
ported toward CSF in the SAS and distributed in a wider area of
the brain.
The above sections show the barriers that NPs or NCs face
when these cross the BBB, and also other potential barriers that
NPs/NCs may utilize to access the brain parenchyma. In the
above sections emphasis is given to particle size, although this
is a major factor, other properties of NPs or NCs such as charge
should be take into consideration for diffusion of NPs/NCs in the
brain parenchyma.
Mechanisms are described in the above sections for crossing
the NPs through the CNS barriers based on published physiolog-
ical literature. However, further studies are required to add more
details about the interaction of NPs with the CNS. Although an-
imal models make valuable contribution to understanding drug
delivery to the brain by NPs, it remains difficult to conduct mech-
anistic studies on the barrier function and interactions with NPs.
Therefore, a microphysiological platform of the BBB was engi-
neered to better understand the transport of NPs through the
BBB. For example, this model allowed authors to determine
that apolipoprotein A1-based NPs (eHNP-A1) crossed the BBB
through the scavenger receptor class B type 1 (SR-B1) via transcy-
tosis. Blocking SR-B1 reduced the transport of the NPs through
the BBB, however, the NPs still crossed the BBB via alternative
transport mechanisms. Therefore, the use of eHNP-A1 was sug-
gested for drug delivery to the brain.[90]
3. Effects of Aging on the BBB
Aging affects both barrier and transport functions of the BBB. In
terms of barrier functionality, by aging, the human BBB perme-
ability increases, in particular to albumin,[91] with human albu-
min having a diameter of 8.5 nm.[92] During aging of the human
brain, the BBB breakdown begins in the hippocampus, which
leads to damage to pericytes.[93] However, the BBB permeability
increases further in patients with either vascular dementia or AD
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Figure 7. A schematic depiction of the glymphatic pathway. This diagram shows that CSF arrives in the brain through paravascular paths, by passing the
glia limitans, washes the brain parenchyma, mixes with ISF, leaves the brain parenchyma through the opposite-side glia limitans, and is cleared from the
brain via paravenous paths. In this diagram, two different sizes of NPs are shown (small and large). Large NPs will stay within the arteriole paravascular
path, while small NPs will cross the glia limitans and reach the brain parenchyma. The small NPs may leave the brain by following the convective flow
of ISF. In addition, large NCs may release their cargo in the basement membrane due to degradation by enzymes such as MMP-9. The cargo would be
distributed within the brain by the convective flow of the ISF in the brain.
compared with age-matched controls.[91] There are several factors
that contribute to the BBB breakdown by aging. For example, acid
sphingomyelinase (ASM) is a critical factor in the integrity of the
BBB and ASM levels increase with aging in the endothelial cells
of human brain, leading to greater BBB permeability through in-
creased caveolae-mediated transcytosis.[94] Furthermore, by ag-
ing microglia are primed to present amplified responses to im-
mune challenges.[95] This is partly due to the presence of dys-
trophic microglia (loss of fine branches) in aged humans.[96] Ac-
tivated microglia disrupt the BBB.[97]
The BBB exchange and transport functionality also change
with aging. For example, it has been found that in adult rats
the transport of anti-TfR antibody (OX26) was decreased with
respect to the brain of younger rats following i.v. administra-
tion of OX26.[98] As another example, the insulin receptor den-
sity decreases with aging in human brain.[99] Insulin-receptor ex-
hibiting cells are present on the luminal membrane of the BBB
and neural cells in the CNS,[100,101] which import blood-borne in-
sulin into the brain via RMT.[100] Efforts to exploit potential use
of insulin for drug delivery via RMT has stalled due to a short
serum half-life of about 10 min and the possibility of hypogly-
caemia (too much insulin will promote widespread uptake of
glucose from the blood circulation).[102] This problem may be
overcome by employing insulin-like growth factors (IGF-1 and
IGF-2),[103] as higher concentrations of IGFs are required to de-
velop hypoglycaemia.[102] Nevertheless, antibody meditated bind-
ing to insulin receptor has been exploited for drug delivery to
the brain.[104] Boado and Pardridge fused a lysosomal enzyme,
𝛼-l-liduronidase (IDUA), with monoclonal antibodies to human
insulin receptor (HIRMAb) to cross the BBB. Upon administra-
tion in rhesus monkeys, 1.2% of injected drug accumulated in
the brain, whereas the unconjugated IDUA did not penetrate the
BBB.[105] It is reported that HIRMAb acts like a molecular Trojan
horse to deliver the IDUA across the BBB by binding to insulin re-
ceptors. Furthermore, they demonstrated the delivery of a decoy
receptor (tumor necrosis factor (TNF) receptor) across the BBB
by fusing it with HIRMAb.[106]
The expression of low density lipoprotein receptor-related pro-
tein 1 (LRP-1) also decreases on the BBB upon aging.[107] This
could affect uptake of NPs that target LRP-1. Therefore, targeting
other receptors as well as LRP-1[108] could be a suitable strategy
for drug delivery to the aged brain by NPs. Likewise, the activity
of P-gp decreases on the human BBB with aging.[109] NP formu-
lations have been developed to silence P-gp on the BBB.[110] This
was to improve the delivery of drugs to the brain by preventing
efflux of drug molecules or NPs taken up by the BBB endothelial
cells back to the blood (Figure 7, return of NP is indicated by red
arrow). However, it should be noted that lower expression of P-gp
may increase accumulation of AD-associated amyloid beta (A𝛽)
deposits in the brain.[111]
There are also morphological changes to the brain blood ves-
sels associated with aging. The tortuosity of cortical arteries in-
creased in aging mice. In addition, older mice had uneven distri-
bution of capillary vessels in the brain, signs of vascular structure
modification with aging.[112] Similarly, microvascular density of
the paraventricular nucleus reduced in humans upon aging.[113]
Astrocyte and pericyte number increase (20% and 22%, respec-
tively) in the cortex of rat brains during aging.[114] Furthermore,
collagen deposits form around the brain blood vessels during
aging,[115] a phenomenon known as microvascular fibrosis.[116]
This could be due to the reduction of the cellular vascular reac-
tivity (CVR) induced by aging (evident in the hippocampus of ag-
ing subjects).[117] CVR is a brain blood vessel response to exter-
nal vasoactive stimuli in the hippocampus, which contributes to
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memory.[117] In addition, microvasculature in the brain become
thickened mostly due to hyalinization.[118] There is an 18% in-
crease in the diameter in the frontal cortex BM (from 50 to 59 nm)
and 32% increase in diameter of hippocampal BM (from 49 to
65 nm) in the rat brain upon aging.[31] Notably, the BM thickness
was almost doubled in aged mice.[119]Similarly, it has been shown
that BM thickness typically increases in humans throughout ag-
ing from 70 nm at fetal age to about 3500 nm (3.5 µm) at age
90.[115] These morphological changes to the brain microvascular
structure would affect the efficiency of NPs reaching the brain
parenchyma and neurons compared to brain in younger ages.
Aging not only brings increased BBB permeability, but also
this involves neuroinflammation as the result of cytokine release
such as interleukin (IL)-1𝛽 and interferon (INF)-𝛾 .[120] It is be-
lieved that such neuroinflammation played a major role in pre-
venting BBB transmigration of inhaled 21.5 nm TiO2 NPs.
[120]
It should be noted that in this study aging caused increased
BBB permeability to small molecules such as atenolol, but not
NPs.[120] In addition, aging was associated with a dramatic de-
cline in the efficiency of exchange between the SAS CSF and the
brain parenchyma.[121] This could lead to impaired glymphatic
flow in the brain, in particular in the BM of the BBB, which could
affect distribution of NPs that crossed the BBB. Lack of NP clear-
ance from the BM of the BBB may increase the chance of return-
ing of the NPs back to the blood via transcytosis.
In summary, the brain microvessels are changed with aging,
and although they become more permeable, deposition of colla-
gen, albumin, micro-hemorrhages, thickened BM, and neuroin-
flammation do not make the barrier easier to bypass by NPs.
It may be suggested that small NPs (perhaps less than 20 nm)
would have a better chance to cross the BBB, bypass the deposited
serum proteins around brain microvessels and reach the brain
parenchyma in aged subjects.
4. Effects of Disease on the BBB
Several diseases affect the BBB function in various aspects. How-
ever, there is a compensatory mechanism in the brain that pro-
tects neurons from exposure to toxic chemicals in the serum. In
the following sections, the effects of brain diseases on the BBB
are discussed, and the consequences are evaluated for targeting
of the brain by NPs.
4.1. Alzheimer’s Disease
The neural vascular unit (NVU) is affected by Alzheimer’s dis-
ease (AD) in several different ways. The deposition of A𝛽 in the
brain is the hallmark of AD, with A𝛽 plaques depositing around
brain vessels.[122] This brings structural damages to the NVU in-
cluding the BBB wall and surrounding extracellular space. In ad-
dition, amyloid fibrils were observed in small leptomeningeal ar-
teries and perforating cortical arterioles of patients with AD.[123]
The deposits were typically between 8 and 10 nm[123] and affect
pericytes, which maintain integrity of the BBB.[124] Accelerated
pericyte degeneration and a reduction in their number have been
shown in AD.[125–127] Furthermore, perivascular microglial pro-
liferation was prominent in the hippocampus of patients with
AD;[127] and A𝛽 deposits caused astrocyte endfeet swelling and
retraction in transgenic arcA𝛽 mice.[128]
The interaction of A𝛽 plaques with the receptor for advanced
glycation end products (RAGE) reduced the expression of TJ
proteins.[129] In addition, the A𝛽 oligomer itself increased the
expression of RAGE, which further reduced the levels of ZO-1,
claudin-5 and occludin.[130] Accordingly, the TJ proteins (claudin-
5, ZO-1 and occludin) were lost in the brain tissues of patients
with capillary cerebral amyloid angiopathy (CAA),[131] as A𝛽 de-
posits were found in the cerebral veins of the majority (78%) of
patients with CAA.[132] These observations show that A𝛽 plaques
affect both morphology and function of the BBB.
Aquaporins are protein channels involved in water transport.
Aquaporin 4 (AQP4) is involved mainly in interstitial brain fluid
homeostasis, including BBB regulation. The expression of AQP4
was significantly higher in AD patients compared to control
subjects.[133] On the other hand, the expression of perivascular
AQP4 decreases with increased A𝛽 deposition.[134] These alter-
ations in the expression of AQP4 may contribute to edema for-
mation in the brains of patients with AD and alteration in the
BBB permeability. At this stage, it is not clear how these changes
in water transport in the AD brain may affect the retention time
of NPs.
In humans, ApoE has three isoforms: ApoE2, ApoE3, and
ApoE4. Carriers of ApoE4 have a major risk factor for AD. The
carriers of ApoE4 show greater breakdown of BBB by age com-
pared to ApoE2 or ApoE3 alleles, which leads to considerable al-
bumin levels in the CSF.[135] Furthermore, brain samples from
AD cases homozygous for ApoE 𝜖4 showed increased deposition
of fibrin(ogen) specifically in CAA and oligomeric A𝛽-positive
vessels compared with AD ApoE 𝜖2 and 𝜖3 allele carriers.[136]
The presence of A𝛽 plaques and elevated RAGE expression
enhanced MMP secretion from the brain capillaries in an an-
imal model of AD.[129] Also A𝛽1-42 (as oligo) increased the lev-
els of MMP-2 and MMP-9 in the brain ECs.[130] Furthermore,
MMP-9 is also accumulated in pericytes of AD ApoE4 carrier
patients.[125] These enzymes further affect the BBB integrity and
make it more permeable. On the other hand, the presence of
these enzymes could open an opportunity for the development
of enzyme-responsive NCs for drug delivery to the brain.[137]
Recent studies identified that serum levels of bile acids in-
creased in patients with AD compared to control subjects.[138–140]
Bile acids (deoxycholic acid and chenodeoxycholic acid) increased
permeability of the BBB by activation of Rac1 followed by phos-
phorylation of occludin, with chenodeoxycholic acid being more
potent.[141,142] The disruption of the BBB occurs more with hy-
drophobic bile acids than hydrophilic bile acids (such as ur-
sodeoxycholic acid).[141] The disruption of the BBB could lead to
microhemorrhages with the release of neurotoxic hemoglobin-
derived products.[143]
As the results of the above findings, the two-hit-vascular hy-
pothesis has been proposed for developing AD.[144] The hypothe-
sis states that first (hit 1) the cerebrovascular vessels get damaged.
This is sufficient to initiate neurodegeneration. In addition, and
perhaps as a result, A𝛽 plaque accumulation (hit 2) further con-
tributes to the BBB damage, and these contribute to developing
AD.[144] Therefore, the increased BBB permeability would be the
start of AD development. It has been suggested that the delivery
of genes to the brain ECs might restore LRP-1 levels at the BBB.
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This is to contribute the clearance of A𝛽 from the brain and min-
imizing BBB damage.[144]
On the other hand, the expressions of ECM proteins (colla-
gen IV, perlecan, fibronectin) increase in the frontal and tem-
poral cortex of patients with AD.[145] The capillary BM thickness
increased significantly in the hippocampus, cerebral cortex and
thalamus of patients with AD.[116,146] This was accompanied by
increased expression of BM proteins (collagen IV, laminin, and
nidogen-2).[146] Unfortunately, this alteration of the BM would re-
duce the drainage of A𝛽 from the brain.[146] It is shown that fib-
rin deposition increases in the AD brain, which correlates with
the degree of disease pathology.[147] Furthermore, brain microb-
leeds have been shown by using magnetic resonance imaging
(MRI) in preclinical AD patients, which further contributes to
the deposition of serum proteins around brain microvessels.[148]
In severe AD, the shrinkage of ECs has been observed.[149] In
addition, expression of glucose transporters at the BBB, which
mediate glucose transport into the brain, decreases in AD lead-
ing to increased BBB leakage.[150] The increased permeability
of the BBB in AD leads to the deposition of albumin,[93,151]
fibrinogen,[152] fibrin,[126,150] IgG,[126,150] and prothrombin[149] in
microvascular segments in particular in those areas that have
A𝛽 deposition.[151,153] Furthermore, the cerebral levels of vitamin
D binding protein (DBP) increase from 0.6 µg mL−1 in control
subjects to 1.2 µg mL−1 in patients with AD[154] to inhibit aggre-
gation of monomeric A𝛽1–42
[155] and prevent BBB microbleeds.
Therefore, although the permeability of the BBB increases in
AD, these compensatory mechanisms would protect the neurons
from harmful materials originating from the serum. These com-
pensatory mechanisms may bring further hindrance for NPs to
cross the BBB.
Table 1 (in vivo) and Table 2 (in vitro) present preclinical ex-
amples for the development of NP formulations in relation to the
treatment of AD. It should be noted that Talamini et al. found that
gold NPs as small as 10 nm could not enter the brain parenchyma
following i.v. administration to adult male CD-1 mice.[156] There-
fore, the penetration of NPs into the brain in the exam-
ples below may indicate compromised BBB in animal models
of AD.
The results in Table 1 suggest that NP sizes both above and be-
low 100 nm have been effective in ameliorating memory deficits
and brain A𝛽 levels in the AD animal models. However, it ap-
pears that sub 100 nm NPs are more potent. The research on
animal models of AD suggest a considerably compromised BBB,
perhaps partly by A𝛽-oligomer disrupted blood-CSF barrier in the
choroid plexus,[174] which may allow the NPs to enter into the
brain parenchyma following exiting from the blood through fen-
estrated blood vessels in the choroid plexus. It should be noted
that NPs may interact with A𝛽 in choroid plexus,[175] and ex-
ert their therapeutic effects. Hence, the clinical outcomes were
similar for both types of NPs (with or without brain targeting
ligand).[161] Nevertheless, NPs with small sizes (70 nm) with
brain targeting ligands could invoke superior therapeutic effects
due to crossing the BL, glia limitans and distribution in brain
parenchyma.[176] It should be noted that expression of TfR de-
creases in the hippocampus of patients with AD compared to
age-matched controls.[177] Therefore, NP uptake may be affected
in AD when NPs utilize transferrin mediated transport across the
BBB.
In terms of using NCs for the treatment of patients with AD,
CERE has been developed, which is an AAV serotype 2 vector ex-
pressing human NGF. These are delivered to the brains of pa-
tients with AD by injection into the brain (a single stereotactic
neurosurgical procedure under general anesthesia). CERE-110
passed phase I clinical testing,[185,186] and has proceeded to phase
II clinical trial with 49 AD patients. Although AAV2-NGF deliv-
ery was well-tolerated, it did not affect clinical outcomes nor did
it modulate selected AD biomarkers. However, in the treatment
group, the mini-mental state exam of some patients increased
four points.[187] It should be noted that pre-existing anti-AAV an-
tibodies prove to be an obstacle in the use of AAVs in gene deliv-
ery to the brain,[85,188] which could necessitate the administration
of AAVs by intracerebral injections to avoid potential interaction
with pre-existing antibodies in the blood.
As explained above, there are several mechanisms that in-
crease permeability of the BBB in patients with AD compared to
age-matched control subjects.[91] These observations lead to the
conclusion that although the BBB may become leaky in AD (an-
imal models), and this would help the NPs crossing the BBB,
the diffusion of NPs may be reduced in the brain due to A𝛽 de-
posits and the extra residues of proteins in the ECM leaked from
the serum as compensatory mechanism to work against the BBB
disruption.[116]
Despite extensive research into novel therapies for AD, the
drug development has proven to be unusually difficult with a
99.6% failure rate in the decade of 2002 to 2019.[189,190] Past clin-
ical trials can provide lessons to apply to future trials and drug
development for AD treatment. One of the lessons that can be
related to NPs is: Ensuring that the drug within the NP enters
the brain and it is not removed from the brain by transporters
such as P-gp.[191]
4.2. Multiple Sclerosis
Dysfunction of the BBB is also a major hallmark of multiple
sclerosis (MS).[192] However, the BBB integrity appears to be
much higher in patients with MS compared to experimental au-
toimmune encephalomyelitis (EAE) mice. There is an extensive
change to the BL in the inflammatory regions of MS lesions.
The BL becomes irregular and discontinuous.[193,194] Niche-like
perivascular areas form in EAE mice that can accommodate neu-
ral stem cells (NSCs) to promote brain repair.[195] Dysfunction
of the BBB is also a major hallmark of MS.[192] TJ protein ex-
pression was decreased in the BCECs, and the loss of ZO-1 was
prominent in patients with MS.[192,196] The disruption allows the
leakage of fibrinogen from the blood into the CNS,[192] and this
can be an activator of microglia.[192] Exposure of ECs to pro-
inflammatory cytokines (IFN- 𝛾 , TNF-𝛼, IL-1𝛽) interrupts the
BBB by decreasing endothelial expression of occludin (disorga-
nizing cell-cell junctions),[197] losing claudin-3 from TJs,[198] de-
creasing expression of ZO-1,[196] and promoting the shedding of
endothelial “microparticles.”[199] The active lesions showed TJ ab-
normalities in the brain of patients with MS, and TJ abnormality
was associated with the leakage of serum protein (fibrinogen).[200]
The hydrodynamic diameter of fibrinogen is about 22 nm.[201]
Despite this observation, the levels of fibrinogen in the CSF
of healthy subjects have been measured to be slightly higher
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Table 1. Recent NP formulations developed in preclinical studies for the treatment of AD. PLGA: poly(lactic-co-glycolic acid).





DBP None 226.6 ± 44.4 i.v. 5× transgenic
mice
Reduced accumulation of
A𝛽 in the brain









135.2 ± 6.8 i.v. AD rats Reduced brain A𝛽 plaques [158]
PLGA Curcumin Selenium 160 ± 5 i.v. 5XFAD Penetrating into the brain [159]
PLA-polyethylene glycol
(PEG)

















None 128.6 i.v. Transgenic AD
mice

















RVG 97 i.v. APP/PS1
transgenic mice














Curcumin KLVFFAED (targeting RAGE) 65 i.v. APP/PS1 mice Significantly improved
memory behavior
[164]
Selenium None CGHKAKGPRK 95 – – Reduced A𝛽 fibrillization








QSH (A𝛽 targeting ligand)
70 i.v. APP/PS1 mice Downregulating BACE1 at
both mRNA and protein
levels
[167]
PEG-gold Anthocyanins None 135 ± 5 i.v. AD mice Reduced A𝛽1–42 induced
memory deficits, the
levels of A𝛽, BACE-1, and
APP
[168]
Liposomes Plasmid DNA Dual targeting 1) Transferrin
protein+ 2) penetratin
(RQIKIWFQNRRMKWKK)
150.4 ± 3.75 i.v. C57BL/6J mice 12% of the administered
dose were found per gram
of brain tissue
[169]
Liposomes Plasmid DNA None NA i.v. C57BL/6J mice 8% of the administered
dose were found per gram
of brain tissue
[169]






None 102 ± 2 i.p. APP/PS1 Reduced the levels of A𝛽
both in serum and the
brain
[171,172]
Chitosan Piperine None 248.50 ± 23.50 Nasal AD mice Improved cognitive function [173]
a)
Intraperitoneally.
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Table 2. Recent in vitro studies of developing NPs for the treatment of AD. Tf: transferrin; TfR: transferrin receptor.





168–189 Reduce A𝛽1-42 aggregationNPs
crossed in vitro BBB model
[178]
SLNP Rapamycin (an mTORC1
inhibitor)







166 ± 2 The cell uptake NPs increased
from 8% (with OX26 only)
to 14% (with DE2B4 and
OX26) by porcine BCECs
[180,181]
Gold None None 30 Inhibiting A𝛽 fibrillization [182]
PEG-SPIONS
c),d)
None None 20 Retarded fibrillization of A𝛽 [183]
a)
Anti-Tf receptor monoclonal antibody
b)
Inhibitor of A𝛽 formation
c)
Superparamagnetic iron oxide nanoparticles
d)
Superparamagnetic iron oxide nanoparticles (SPIONS)
were withdrawn from the market due to safety issues.[184]
(3.84 µg mL−1) than CSF levels of patients with MS (< 2 µg
mL−1).[202,203] These observations indicate again that NCs/NPs
should be less than 20 nm to cross the BBB in patients with MS
due to its dysfunction. Larger NCs/NPs will require crossing the
BBB endothelial cells via transcytosis.
Neuropilin 1 (NRP1) is highly expressed in the brain endothe-
lial cells of patients with MS, in particular in the early active de-
myelinating lesions;[204] and the interaction of IFN-𝛾 and NRP1
may contribute to the dysfunction of the BBB in MS.[204] Fur-
thermore, secreted protein acidic and rich in cysteine (SPARC)
is a cell-matrix modulating protein that is involved in endothe-
lial barrier function. SPARC reduced ZO-1 and occludin expres-
sion in a model of the BBB, and promoted the permeability of
the BBB in a concentration dependent manner.[196] As cerebral
blood vessels become intensely SPARC positive in EAE mice,
then SPARC would further contribute to enhanced BBB perme-
ability in MS.[196]
Peripheral blood lymphocytes have greater ability to degrade
laminin in MS patients compared to normal controls.[205] In MS,
the breakdown of the BBB facilitates leukocyte transmigration
to the lesions via recognition of vascular adhesion protein 1.[206]
Furthermore, SPARC may promote transmigration of leukocytes
across the BBB.[196] In addition, the serum levels of MMP-9 were
increased in patients with MS and this could contribute to the
breakdown of the BBB.[207] To maintain the integrity of the BBB,
MS patients present elevated hedgehog signaling components in
the brain[208] and the astrocyte-secreted Sonic hedgehog is es-
sential for the integrity of the BBB.[208] The presence of leuko-
cytes around the BBB may increase up take of NPs that crossed
the BBB, hence, reducing the number of NPs reaching the brain
parenchyma.
The leakage of the BBB in MS suggests that NPs would reach
the neurons in the brain more effectively compared to the healthy
BBB following i.v. administration. In the following, examples are
provided. NPs of PLGA with a size of 217 nm were injected
intravenously into EAE mice and small amounts of NPs were
subsequently found in the brain. It was suggested that the NPs
penetrated into the brain via a leaky BBB and choroid plexus
in EAE mice.[209] In another study, nanoliposomes with a size
of 80 nm penetrated into the brain tissue of EAE mice 3–6
fold more than control (normal) mice following i.v. administra-
tion. It should be noted that the amount of liposomes in the
brain was about 3% of injected dose per mg of brain tissue.[210]
Nanoliposomes with an average size of 74 nm had the same
therapeutic effects as targeted-nanoliposomes to the brain in
EAE mice.[211] Nontargeted nanoliposomes (nanosterically sta-
bilized liposomesn (SSL); 80 nm in diameter) contained the
prodrug prednisolone and showed a five-fold higher therapeu-
tic efficacy than the free drug. This was attributed to the accu-
mulation of nSSL in the brain due to compromised BBB.[212]
Cerium oxide NPs (2.9 nm diameter) also penetrated into the
brain of EAE mice.[213] In addition, very small superparamagnetic
iron oxide particles (VSOPs) with a hydrodynamic diameter of
7 nm penetrated into the perivascular inflammatory lesions of
EAE mice following i.v. administration.[69] VSOPs were also ob-
served in the choroid plexus.[69] In addition, pomegranate seed
oil nanodroplets had diameters of 30 and 180 nm, but the larger
size nanodroplets were more effective in the treatment of EAE
mice following oral administration.[214] Finally, curcumin den-
drosomes decreased the scores of disease in EAE mice following
intraperitoneal (i.p.) administration;[215] and the effects of cur-
cumin dendrosomes (size of 142 nm[216]) were attributed to its an-
tiinflammatory effects by regulation of T helper 2 cytokines.[215]
These studies suggest that in mouse model of MS, NCs in a wide
size range of 2.9–217 nm can penetrate into the brain tissue, due
to the leaky BBB.
The NP accumulation profile changes in the brain of pa-
tients with MS, compared to animal models of MS. Ultra-
small superparamagnetic iron oxide NPs (USPIOs) with size
of 20–40 nm diameter[217,218] showed a lower abundance in the
brain lesions of patients with MS compared to gadolinium-
diethylenetriaminepentaacetic acid (DTPA) (MW = 938 Da).[219]
It was suggested that USPIOs accumulated inside phagocytic
cells. Hence, USPIOs showed infiltration of macrophages into
the brain.[219] This could indicate that in MS patients, the per-
meability of the BBB increases only for small molecules such
as gadolinium-DTPA, but less for small NPs such as US-
PIOs. This could be due to the leakage of serum proteins
such as fibrinogen[200] into the BL and creating a secondary
barrier.
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4.3. Ischemic Stroke
Ischemic stroke is the reduction of cerebral blood flow to the
brain due to the obstruction of arteries, usually by blood clots.
Ischemic stroke can cause death or disability. In ischemic stroke
the levels of MMP-2 are known to increase in the ischemic core
of nonhuman primates,[220] which contributes to the degrada-
tion of the BL. In addition, the levels of MMP-9 were found
to be increased in the ischemic brains of nonhuman primates,
leading to intracerebral hemorrhage.[221] It is estimated that
the BBB opening occurs with an average of 6.8 h after onset
of ischemia in humans.[222] This situation may hint at a de-
livery window for brain-targeting NCs/NPs in the early hours
of the stroke, also after reperfusion, when there is a greater
chance of BBB disruption.[222] The BBB disruption is associ-
ated with intracerebral hemorrhage (hemorrhage transforma-
tion) and poor clinical outcomes.[222] These studies suggest that
MMP inhibitors would reduce neuronal damage and subsequent
disability in ischemic stroke, as shown in animal studies.[223] Fol-
lowing stroke, there is an excessive water accumulation in the
BL.[224] Also it has been shown that the degradation of BL pro-
teins occurs following subarachnoid hemorrhage and cerebral
ischemia.[225,226]
A question may be raised that in a brain ischemic stroke, when
the blood vessels are blocked, how can NCs get access to the is-
chemic areas? It has been shown that 100 nm liposomes accu-
mulate in the ischemic core and penumbra region when they are
intravenously injected into a permanent middle cerebral artery
occlusion (p-MCAO) rat model despite a significant reduction in
the cerebral blood flow.[227] Positron emission tomography (PET)
showed 100 nm 18F labeled PEG liposomes accumulating in the
ischemic core; but they started accumulating in the penumbra re-
gion first and then gradually moved toward the ischemic core.[228]
It should be noted that liposomes were not tagged with brain-
targeting ligands, and the accumulation was due to enhanced
permeability and retention (EPR).[228] Figure 8 shows the PET
imaging of 18F labeled PEG liposomes in the ischemic region of
p-MCAO rats.[228] The red arrow indicates the ischemic region.
It can be seen from this figure that liposomes were spread in
the brain, apart from the ischemic core. However, the liposomes
started filling the surrounding region of the ischemic core and
gradually progressing toward the center. The presence of the lipo-
somes in the brain would be due to crossing of the disrupted BBB
at the penumbra region. Also, this study would suggest the ISF
flow around the core, but impaired at the core-center,[229] which
leads to gradual progression of the liposomes to this area. It has
been shown that the ischemic stroke impairs ISF drainage, in
particular along occluded vessels.[229]
In a recent study, block copolymers were produced containing
either NH2-norleucine-TPRSFL-C-SH, a thrombin-cleavable pep-
tide (T), or NH2-LGRMGLPGK-C-SH (M), a MMP-9-cleavable
peptide.[230] The block copolymers were obtained by conjugating
the PEGylated peptides to poly(𝜖-caprolactone) monomers.
PEG-T-poly(𝜖-caprolactone) or PEG-M-poly(𝜖-caprolactone)
monomers were used to form NCs by precipitation, and these
were cleavable by thrombin, or MMP-9, respectively.[230] The
PEG-T-poly(𝜖-caprolactone) NPs expanded from sub 100 nm
size to over 1000 nm size after 24 h incubation with thrombin.
A similar observation was made for PEG-M-poly(𝜖-caprolactone)
Figure 8. PET imaging of [18F]-labeled PEG-liposomes in the ischemic re-
gion of p-MCAO rats. p-MCAO rats were injected intravenously with [18F]-
labeled PEG-liposomes at 1 h after the onset of occlusion. The distribution
of [18F] Step 2 was determined for 2 h with the Clairvivo PET system. Each
single image for every 10 min period was obtained by integration of the to-
tal photon numbers during this period. The arrow indicates the ischemic
region, and the right hemisphere of these images shows the ischemic side.
Reproduced with permission.[228] Copyright 2014, International Center for
Artificial Organs and Transplantation and Wiley Periodicals, LLC.
NPs in the presence of MMP-9. The aim of the expanding NCs
was to prevent return of NCs from the abluminal side of the
BBB to the luminal side by transcytosis. To add therapeutic
benefits, the NCs encapsulated glyburide to deliver the drug to
the ischemic brain (following i.v. administration), and surface
conjugated with plerixafor (AMD3100, an immunostimulant) to
target the ischemic region of the brain.[230] AMD3100-conjugated
NCs were administered i.v. to transient-MCAO (t-MCAO) mice.
The NCs demonstrated greater specificity to the ischemic re-
gions, as the levels of the C-X-C chemokine receptor type 4
(CXCR4) expression were significantly elevated in the ischemic
brain (AMD3100 is an agonist to CXCR4 receptor).[230] This is
interesting, as in an ischemic brain, the presence of NCs will
be required only in the ischemic regions. It was found that the
glyburide-loaded AMD3100-conjugated NCs improved mouse
survival by about 50% over 7 days, reduced infarct volume by
36%, and improved neurological scores on a five point scale
from 5 (no spontaneous motor activity) to almost 1 (normal
motor function).
In a similar approach, PEGylated lipid NPs were conjugated
with Fas ligand antibody (Fas-PLNPs), and Fas is selectively ex-
pressed in brain ischemic region.[231] The NPs had a size of
60.97 ± 7.95 nm, while non-Fas-antibody conjugated control NPs
were smaller (38.23 ± 3.22 nm). Non-Fas-antibody conjugated
NPs accumulated in the brain following i.v. administration to t-
MCAO mice, but in a wider region not exclusive to the ischemic
region. This suggests that NCs crossed the BBB due to increased
permeability of the BBB in the ischemic and penumbra regions,
but the small size of the NPs allowed spreading in the brain both
by diffusion in the brain parenchyma and convection dislocation
by the ISF flow in the brain. Exclusive localization of Fas-antibody
conjugated NPs at the ischemic region would suggest NP
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Table 3. Summary of recent research work on the delivery of NPs for the treatment of ischemic stroke.
Nanocarrier Drug targeting Ligand Size [nm] Route Model Remarks Ref.






96.24 ± 1.13 i.v. MCAO-rat Liposomes remained in the ischemic
region after 24 h significant
decrease of cell death much






BBB and hence allows
more NCs to cross the
BBB)





151.8 i.v. MCAO-mouse NPs reduced the infarct area (from
40% to 20%)
[236]




None 126.8 ± 3.1 nm i.v. MCAO-rat tPA administered i.v. prior to
administration of NPs to activate
MM-2 and MMP-9 leading to
increased BBB permeability
Fasudil liposomes significantly
suppressed brain cell damage
[237]
PEG-liposomes Asialo-erythropoietin None ND i.v. t-MCAO-rat Liposomes prevented brain damages





the paralysis of the right paw
[238,239]
Liposomes Fasudil None 100 i.v. t-MCAO-rat Reduced infarct volume (from 0.4 to
0.2 cm3)
Improved motor function deficits
(from motor score 9 to motor
score 12 on a 21-point neurological
assessment scale)
[240]
squalenoyl adenosine Adenosine None 120 i.v. ischemic-
reperfusion rat
model
Reduced infarct volume from 54 ± 3
mm3 (vehicle treated) to 24 ± 4
mm3
[241]
PLGA-PEG Thyroid hormone Glutathione 326.6 i.v. MCAO-mouse As well as NPs coated with






TfR antibody 637 ± 2 i.v. MCAO-mouse with
reperfusion
NPs reduced infarct volume from 43
± 4 mm3 (control) to 3 ± 2 mm3.
NPs released sufficient amounts of
the active ingredient to prevent




N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone. AEPO: Asialo-erythropoietin
surface attachment in the ischemic region was the contributing
factor.[231] The Fas-PLNPs were loaded with 3-n-butylphthalide
(a neuroprotective agent in ischemic stroke), and administered
i.v. to t-MCAO mice, which improved clinical scores (reduced in-
farct area and neurological deficits) compared to administration
of the drug alone.[231] Table 3 presents part of recent work on the
treatment of ischemic stroke by NPs. There is a secondary brain
damage in cerebral ischemia-reperfusion injury. Reperfusion is
considered to be initial restriction of blood supply followed by
subsequent vascular restoration and concomitant reoxygenation
of downstream tissue.[232]
Comparing the above results and findings in Table 3 suggests
that the BBB is more compromised in a MCAO-mouse model
compared to a MCAO-rat model. Hence larger-untagged NPs
(about 300 nm) can cross the BBB in a MCAO-mouse model,
while only smaller NPs (about 100 nm) can cross the BBB in a
MCAO-rat model. Furthermore, NPs without brain targeting lig-
ands were administered i.v. and reduced infarct volume, with im-
proved motor function in rat ischemic stroke models, indicating
compromised BBB.
The translation of animal studies to human trials is one of the
biggest challenges in the study of neuroprotection in stroke.[233]
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In a personalized stroke therapy, it is important to identify the
stage of the stroke. This goal may be achieved by using NPs.
These may be employed to identify biomarkers (usually in small
quantities) in the brain and help visualization by MRI.[233] The
following factors should be considered in personalized therapy
for stroke: age, infarct size, location, and collateral circulation.[233]
However, one particular question needs to be addressed: why, af-
ter so many NP formulations for stroke, aren’t any reaching clini-
cal trial? At the moment a clear answer cannot be provided. How-
ever, the intrinsic embolic features of the particles may be an is-
sue, requiring further investigation and resolution to this poten-
tial problem. Furthermore, a rapid therapeutic action is required
from NPs within few hours from the onset of the ischemia. Fi-
nally, the main therapeutic goal is to remove the blood clot in the
brain shortly after ischemic stroke.
Hence, the research on NPs perhaps should take these desired
effects into consideration.
The above observations indicate that the BBB permeability in-
creases in ischemic stroke, which allows the crossing of small
(100 nm) NPs in animal models. However, this is transient.[222]
Then, perhaps, the secondary compensatory microvascular bar-
rier in ischemic stroke is not as strong as compensatory barriers
in MS or AD. However, for effective NC delivery to the brain,
these need to be tagged with brain-targeting ligands as well as
ischemic zone-targeting ligands. It should be noted that the NPs
in the systemic circulation may adsorb serum proteins, which is
called the formation of protein corona. This protein layer makes
NPs susceptible for uptake by macrophages, which would reduce
the number of NPs reaching the brain. One way around this
could be pre-coating the surface of NPs with targeting proteins
(known as protein corona shield). This approach not only may
preserve the targeting ability of the NP, but also may reduce the
adsorption of protein serums. This way, the elimination of the
NPs may be reduced by macrophages. It should be noted that
the targeting ligand itself is a protein with a large mass such as
36.3 kDa.[244]
4.4. Parkinson’s Disease (PD)
Lysosomal storage disorders are implicated in pathogenesis of
neurodegenerative diseases, notably PD. In this disease, the lyso-
somes have impaired acidic function and impaired proteolytic
enzymes, which lead to dysfunction in clearance and recycling
of proteins and cell organelles. Hence, debris start to accumu-
late in the cells. To alleviate this, NPs provide the opportunity to
restore acidic pH and proteolytic activity of lysosomes,[245] which
form a complex with 𝛼-synuclein (𝛼-Sync, a presynaptic neuronal
protein that is linked to neuropathology of PD),[246] or suppress
𝛼-Sync over-expression through RNA interference.[247]
Preclinical studies are presented in Table 4 for the treatment
of PD by using NPs. It can be seen that all routes of administra-
tion have been investigated. The NPs had brain-targeting ligands,
when i.v. or i.p. routes were approached. These indicate the rela-
tively high impermeability of the BBB in PD compared to other
brain diseases such as the ischemic stroke, although increased
permeability of the BBB has been identified in patients with
PD.[248] Interestingly, PAMAM dendrimers decorated with lacto-
ferrin were able to deliver plasmid DNA (encoding human glial
cell-line derived neurotrophic factor) into following i.v. adminis-
tration. NPs were effective in improving locomotor activity.[249] As
long-term therapy is required for the repair of degenerated neu-
rons and maintenance of the health of existing neurons, then in-
tranasal delivery could provide better patient’s compliance com-
pared to i.v. injections. Data in Table 4 shows improved mo-
tor activities following intranasal administration, although clin-
ical trial (Phase II) of intranasal reduced glutathione did not
show superior improvements in PD motor scores compared to
placebo.[250]
To enhance neurogenesis in the subventricular zone of the
adult mammalian brain, Saraiva et al. formulated PLGA NPs with
positively charged surfaces using protamine sulfate. MicroRNA-
124 was surface adsorbed to these NPs and administered in-
tracerebrally into mouse models of PD, with outcomes showing
miRNA-124 NPs improved motor activity of the animals.[251]
Recombinant human platelet-derived growth factor-BB
(rhPDGF-BB) reduced PD symptoms and increases dopamine
transporter binding in animal models.[260] In a phase I clinical
trial rhPDGF-BB was injected intracerebroventricularly into
12 PD patients at the maximum dose of 5 µg per day for 12
days. At the end of the trial, all patients had improved motor
examination scores.[261] In terms of using NPs in the clinic for
the treatment of PD, CERE-120 is an experimental AAV that was
engineered to deliver the human gene for neurturin. This vector
was also delivered via intracerebroventricular injection.[262,263]
CERE-120 was investigated in two clinical trials with 50 patients.
The outcomes were not better than placebo; however, there were
improved measures that indicated potential benefits. Therefore,
CERE-120 was investigated in another trial (Phase II) with ≈52
patients (https://clinicaltrials.gov/ct2/show/NCT00985517). In
addition gold nanocrystals (CNM-Au8) have been developed with
the size of 13 nm[264] that are administered orally to patients with
Parkinson’s disease. CNM-Au8 NPs are clean-surfaced, faceted
nanocrystals of gold, which upon administration distribute in
organs including the brain and promote the oxidation of nicoti-
namide adenine dinucleotide hydride (NADH) to the critical
energetic co-factor, NAD+. NADH oxidation drives cellular res-
piratory and metabolic processes that play key roles in the brain
energetically demanding process of myelination.[264] Therefore,
these gold nanocrystals will change the brain metabolism to
repair damages. CNM-Au8 nanocrystals are now in Phase 2
clinical trial (NCT03815916).
The above studies do not indicate significant breakdown of the
BBB in PD. Hence, nasal delivery, use of brain targeting ligands,
or intracerebral injections was employed to cross/bypass the BBB
for the delivery of NPs in PD. Therefore, NPs should have brain
targeting ligands as well as suitable dimensions (preferably less
than 120 nm, but ideally 10 nm) to cross the BBB and reach the
brain parenchyma via i.v. injections or oral administration. The
choice of brain targeting ligand is important, as lactoferrin may
allow larger NPs (about 200 nm) to cross the BBB compared to
transferrin conjugated NPs.[265]
4.5. Brain Tumors
Brain tumors are categorized to primary and secondary in-
tracranial tumors.[266] Primary tumors arise from cells within
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Table 4. The summary of NP formulations that have been developed in vitro or in vivo for the treatment of PD.




PLGA None None 50–100 Intracerebral
injection
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a)
196 ± 10.1 i.v. PD rat models (6-
hydroxydopamine-
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NPs improved locomotor activity of
the animals following five
alternate day injections (three
before the formation of brain
lesions and two after brain
lesions)
NPs significantly enhanced
exogenous gene expression in the
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RA-NPs increased mRNA levels of
Pitx3 (a transcription factor) and
resulted in a significant decrease





UCN None 114.8 ± 5.6 Intranasal PD rat model Systemic adsorption of NPS and
accumulation in the liver
Conjugating NPs with OL
increased accumulation of NPs in
the brain compared to
unconjugated NPs
UCN loaded NPs reduced the
number of rotations (a behavioral
test representing loss of
dopaminergic neurons) in rat
models of PD compared to
untreated control PD model
animals
[256]
Chitosan Selegilline hydrochloride Tween 80 303.39 ± 2.01 Intranasal In vitro Release of active ingredient over 28
h
[257]
Gold nanoflowers l-DOPA (via LAT-1)
e)




Mammalian cationic iron-binding glycoprotein, which belongs to the Tf family
b)
Urocortin (UCN), a corticotropin-releasing hormone family of peptides (4 kDa, around
40 amino acids) with restoration of nigrostriatal function property
c)
Retinoic acid (RA) plays an essential role in the commitment, maturation and survival of neural cells
d)
Odorranalectin (OL) is a small molecule of the lectin family with minimal immunogenicity and bioadhesive properties
e)
LAT-1: Large neutral amino acid transporter.
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the CNS,[267] while secondary tumors are metastases from can-
cers elsewhere in the body.[266] Primary brain tumors account
for 1.6% of all cancer cases,[268] and malignant gliomas are
the most deadly and common brain tumors.[269] Gliomas arise
from glial or precursor cells and include astrocytoma (includ-
ing glioblastoma), oligodendroglioma, ependymoma, oligoas-
trocytoma (mixed glioma), and malignant glioma.[270] Among
gliomas, glioblastoma accounts for the majority of gliomas[270]
and is the most lethal primary brain tumors in adults,[267] with a
median survival of 16 months.[271] As a result, intensive research
has been conducted to identify suitable treatments for glioblas-
toma. In the following section, part of recent NP based therapeu-
tic formulations is discussed. It should be noted that the BBB is
relatively intact at the early stages of developing brain tumors.[272]
Carbon nanotubes (CNTs) have cylindrical shape and are com-
posed of graphene sheets with sp2 hybridized carbon atoms.
Among drug delivery systems, CNTs have emerged as promis-
ing platforms to cross the BBB and deliver therapeutic agents
to brain tumors. CNTs can have single (SWCNT) or multiple
walls (MWCNT).[273] Malignant gliomas are the most common
fatal brain tumors, due to their ability to escape a local im-
munosuppressive microenvironment. To overcome this, CpG
oligodeoxynucleotides (Toll like receptor 9 agonists) were con-
jugated with SWCNTs, and delivered by intracranial injection
to mice bearing intracranial GL261 gliomas. Animals remained
tumor-free for more than three months.[274] Fan et al. also em-
ployed CpG conjugated CNTs for the treatment of metastatic
brain tumors in mice bearing brain B16.F10 melanomas as well
as subcutaneous tumors. The NPs were administered by intra-
tumoral injections by stereotactic administration. It was found
that mice recovered from both tumors, showing that an im-
proved immunosuppressive response in the brain microenviron-
ment was sufficient to suppress the subcutaneous tumor too.[275]
Chemically functionalized MWCNT were able to cross the BBB
at significant amounts between 1 and 4 h post i.v. injections. The
NPs had diameter of 9.2 ± 2.7 nm with a length of 396 ± 290 nm.
The NPs were not conjugated with brain targeting ligands.[276]
Oxidized multi-walled carbon nanotubes were conjugated
with angiopep-2 (TFFYGGSRGKRNNFKTEEY) by using DSPE-
PEG2000-MAL and loaded with doxorubicin (DOX-O-MWCNT-
PEG-ANG). Angiopep-2 targets the LRP receptor on the BBB
as well as glioma cells. The NCs had 10 nm diameter with the
length of 120 nm. DOX-O-MWCNT-PEG-ANG NCs were admin-
istered i.v. to mice bearing intracranial C6 glioma. The median
survival time for DOX-O-MWCNT-PEG-ANG NCs was 43 days,
better than the 36 days for angiopep-free DOX-O-MWCNT NCs.
In vivo fluorescence imaging of brains also showed slight de-
crease of fluorescence intensity for DOX-O-MWCNT NCs com-
pared to DOX-O-MWCNT-PEG-ANG formulation (Figure 9).[277]
This study also indicates that NPs around 100 nm may target
brain parenchyma through compromised BBB and EPR effects
brought about by the glioma. Figure 9 shows dispersion of DOX-
O-MWCNT NCs in other regions of the brain as well as the tumor,
suggesting redistribution of the NPs in the brain due to the CSF
recirculation in the brain.
However, neurotoxicity is the main obstacle in the application
of CNTs for the treatment of brain diseases.[278–280] CNTs affect
brain neurons: CNTs were found to have negative behavioral ef-
fects including increased pacing distances and times necessary
to locate a platform following i.p. injection into rats.[281] It has
also been shown that functionalized CNTs caused the release of
inflammatory cytokines in the mouse brain, following cortical
stereotactic administration.[282] These observations may be the
reason that there have been no clinical trials for the use of CNTs
for the treatment of brain glioblastoma.
Liposomes containing doxorubicin have also been employed
in the treatment of brain tumors in mice. The surface of lipo-
somes was decorated with a tumor-specific pH-responsive pep-
tide H7K(R2)2 (Ac-RRK(HHHHHHH)RR-NH2), and the antitu-
mor activity of the liposomes (DOX-PSL- H7K(R2)2) were investi-
gated in C6 tumor-bearing nude mice. The liposomes had a size
of 92 ± 3.9 nm.[283] These were administered i.v. and reduced sig-
nificantly the growth of tumors. In addition, liposomes without
H7K(R2)2 targeting peptide reduced significantly the growth of
tumors compared to control animals, but not as much as DOX-
PSL- H7K(R2)2 liposomes.
[283] It should be noted that the peptide
is specific to tumors not the BBB.
In another study, enzyme responsive NPs were developed for
the treatment of glioma. These NPs had a core made of gelatine,
degradable by MMP-2. The surface of the gelatine NPs was conju-
gated with gold NPs carrying doxorubicin and a glioma-targeting
peptide RRGD (G-AuNPs-DC-RRGD), where RRGD presents the
conjugation of R8 (RRRRRRRR) to cyclic RGD peptide with a
terminal cysteine (Cys-c(RGDfK), cysteine was conjugated to the
branch of lysine).[284] The NPs originally had a size of 188 nm, but
in the presence of MMP-2, they shrank to 55 nm. I.v. injection of
G-AuNPs-DC-RRGD NPs led to the accumulation of the NPs in
the glioma of C6 cell xenograft-bearing mice. The NPs started
to accumulate in the tumor 4 h post injection.[285] These obser-
vations may suggest that parts of NPs were digested by serum
MMP-2 enzyme and the accumulation of NPs in the glioma was
due to their subsequent reduced size. In this regard, enzyme re-
sponsive NPs have been developed that contained monoclonal
antibodies for the treatment of brain tumors.[286] These NPs were
decorated with 2-methacryloyloxyethyl phosphorylcholine target-
ing two receptors on the BBB: 1) the nicotinic acetylcholine recep-
tor, 2) the choline transporter. The core of NPs contained a pep-
tide (VPLGVRTK) responsive to tumor-derived MMP-2. The NPs
had an average diameter of 25 nm, and these crossed the BBB fol-
lowing i.v. injection and degraded in the brain by tumor-derived
MMP-2. The administration of NCs containing mAbs resulted
in significantly higher CSF mAb concentrations in comparison
to those receiving mAbs alone. For example, mice injected with
native nimotuzumab showed a CSF concentration of 0.084 µg
mL−1 at 12 h which corresponded to 0.1% of the plasma concen-
tration. Conversely, the CSF concentration of the mice injected
with mAb NCs was tenfold higher at 12 h (0.85 µg mL−1) than
those treated with native nimotuzumab. This corresponded to
1.1% of the plasma concentration.[286] These observations sug-
gest that both size and the presence of brain targeting ligands (for
two receptors) on the NPs played key roles in high brain delivery
of mAbs. It should be noted that the molecular weight of MMP-2
(72 kDa)[287] is close to bovine serum albumin (66.5 kDa, hydro-
dynamic diameter: 6.8 nm) or hemoglobin (64.5 kDa, hydrody-
namic diameter: 5.5 nm),[288] hence, the hydrodynamic diameter
of MMP-2 would be around 7 nm. Therefore, enzyme-responsive
NPs should have channels greater than 7 nm to allow the access
of this enzyme to the cleavable sites.
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Figure 9. In vivo fluorescence imaging of brains collected from Balb/c mice after intravenous injection at a dose of 5 mg DOX-equiv. kg−1 body weight.
a) DOX-O-MWNTs-PEG-ANG group is shown on the upper row, b) DOX-O-MWNTs-PEG group is on the middle row, and c) DOX group is on the lower
row. It can be seen that NCs without targeting ligands achieved a considerable accumulation in the brain. Reproduced with permission.[277] Copyright
2012, Elsevier.
Legumain is a lysosomal cysteine protease,[289] which is local-
ized in lysosomes and endosomes.[290] It is suggested that legu-
main extracellular levels increase in cancer.[290] Based on this gold
NPs have been developed that are responsive to legumain. In this
approach gold NPs are linked via a peptide sequence (Ala-Ala-
Asn-Cys-Lys) responsive to legumain. These gold NPs were ad-
ministered with other gold NPs, which carried 2-cyano-6-amino
benzothiazole on the surface (AuNPs-CABT). Following i.v. in-
jection of these NPs (no brain-targeting ligand) to orthotopic C6
glioma-bearing mice, the NPs were accumulated in the brain tu-
mor through the EPR. Legumain cleaved the Ala-Ala-Asn-Cys-Lys
peptide and exposed 1,2-thiolamino groups on cysteine, which
reacted with the cyano groups 2-cyano-6-amino benzothiazole on
the surface of AuNPs-CABT NPs via click cycloaddition. This con-
jugation led to the aggregation of gold NPs and, therefore, pre-
vented the return of NPs back to the blood. In one formulation,
gold NPs carried doxorubicin on the surface, which resulted in
improved survival of the animals.[291] It should be noted that the
accumulation of gold NPs in the body may have negative effects
on the gold NP accumulation organs such as the liver.[292]
There are NP-based drug delivery systems for the treatment
of brain tumors that have made their ways to clinical trials
(Table 5). For example, AGuIX NPs have been in clinical tri-
als (registrations: NCT04094077, NCT02820454, NCT03818386).
These NPs have sub-5 nm sizes and are made of a polysiloxane
matrix and gadolinium chelates. These NPs are injected intra-
venously, and cause radiosensitization of the cells that uptake
these NPs. Radiotherapy of these cells cause the release of ROS
from lysosomes, which leads to cell apoptosis.[293] One of the
main advantages of AGuIX NPs is rapid clearance from the body
via kidneys and lack of accumulation in the liver.[294] Interest-
ingly, many of NP formulations do not have brain targeting lig-
ands (Table 5). Then brain drug delivery would be via the EPR.
Only folic acid and antibodies have been employed as brain tar-
geting ligands. The lack of safety data for peptide-based brain tar-
geting ligands could be one of the reasons for them not being in
clinical trials. Most of the NP formulations have sizes less than
200 nm.
In a recent work, real time-MRI was employed to guide a
catheter via intra-arterial administration to the proximity of the
brain tumor. Then the BBB was opened locally by administra-
tion of mannitol, which was followed by administration of beva-
cizumab to be taken up by the tumor.[295] This approach may be
applied for drug delivery to the brain by NPs.
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The above studies suggest the increased permeability of the
BBB in brain tumors. This can be supported by a recent work
that major facilitator domain containing protein 2A (Mfds2a)
is enriched in CNS vasculature, and Msfd2a helps BBB main-
tain impermeability by reducing the EC transcytosis transport
mechanism.[296] Loss of Mfsd2a in brain endothelial tumors re-
sulted in increased BBB leakage.[297] The above studies indicate
that NCs in sizes less than 100 nm would cross the BBB in the
malignant regions without needing to employ brain-targeting lig-
ands, although the presence of these ligands improves drug de-
livery to the brain.
4.6. BBB Leakage in Other Diseases
As well as the above brain diseases, the BBB permeability in-
creases in other diseases too. In the following part of these
are explained. Vascular bags were observed around the ECs of
patients with cerebral small vessel disease, driving remodeling
of microvasculature.[308] In the brain tissues of autism spec-
trum disorder (ASD) subjects, levels of MMP-9 are significantly
increased[309] contributing to an impaired BBB. In diabetes, there
are changes to the microvascular structure of the brain, and it
has been shown in a mouse model of diabetes that the BBB
changes by a reduction in the number of astrocytes and degen-
eration of pericytes.[310,311] In vitro studies showed that inflam-
mation (acute bacterial infection) caused the BBB to become per-
meable to albumin,[312] however, in vivo studies showed that this
was not always the case.[313]
It needs to be mentioned that the BBB presents different re-
ceptor profiles, depending on the disease. In this regard, Chen
et al. demonstrated that brain targeting ligands should be cho-
sen based on the brain disease since a particular brain targeting
ligand may be suitable for one disease but not for another. This
study found that AAVs presenting a WPFYGTP epitope showed
35 times more efficiency in targeting the brain than the liver. In-
terestingly, AAVs with epitopes for brain microvessels of wild-
type mice were not effective for the mucopolysaccharidosis type
VII mouse brain. This study also shows that brain neurons and
parenchyma may be supplied with enzymes by targeting brain
microvessels with AAVs carrying genes for those enzymes.[314]
Hypertensive encephalopathy[315] and acquired immune defi-
ciency syndrome (AIDS) result in BBB disruption.[316,317] In dis-
eases such as AIDS, where movement of immune cells (in and
out of the CNS) is enhanced, BBB disruption is evident due to
diapedesis (the passage of blood cells through the intact walls of
the capillaries).[318] Chronic pain and intense inflammation in an-
imal models have been reported to cause BBB disruption.
It has been suggested that BBB permeability increases in or-
nithine transcarbamylase deficiency,[319] with excess ammonia
crossing the BBB in these patients and being converted into
glutamine. The excess glutamine increases brain osmotic pres-
sure, which leads to brain edema and neurological damage.[320]
To alleviate the excess ammonia in circulating blood, PEGy-
lated liposomes (MRT5201) have been developed with the size of
16 nm that encapsulate codon-optimized human ornithine tran-
scarbamylase mRNA to target the liver.[321,322] These NPs are now
in a clinical trial (NCT03767270), although the clinical trial is on
hold for further toxicology data on clearance time.[323]
In conclusion, the BBB disruption occurs in other diseases
apart from the main neurodegenerative diseases. Therefore, NP
based drug delivery systems may be developed to minimize neu-
rological damages due to increased BBB permeability. Most im-
portantly, the BBB receptor profile changes with the disease, and
this may require optimizing the brain targeting ligands based on
the modified version of BBB receptor profile.
5. In Vitro Methods for the Assessment of Drug
Delivery to the Brain
Permeability of brain microvasculature contributes significantly
to the efficacy of drugs at sites within the CNS. Therefore, there is
much effort to understand the BBB, to simulate its barrier mech-
anisms and to model therapeutic delivery strategies, pathologies,
or toxicological insults that may overcome them. The preclinical
development of drugs directed toward CNS targets for the treat-
ment of CNS diseases involves complementary modeling meth-
ods. These include in vivo (live animal), in vitro (cell culture) and
in silico (computation based on physiochemical and physiologi-
cal parameters) approaches.
Although in vivo animal models are considered the gold stan-
dard of preclinical predictive tools,[324] it is estimated that 80% of
drug candidates identified this way later fail in clinical trials.[325]
In vivo work is relatively low throughput, expensive and limited
by ethical considerations. In vitro models that attempt to recapit-
ulate the anatomical and physiological barrier properties, which
determine drug delivery across the BBB, are therefore desirable
to inform in vivo work and justify clinical developments. How-
ever, no standard in vitro screen has yet been agreed for assessing
brain uptake,[324,326] rather modifications and different methods
are continually being proposed to improve simulations of barrier
characteristics.[327]
Here we review, using illustrative examples, developments in
alternative in vitro methods to simulate the BBB and experimen-
tal designs that have validated them as tools to assess drug de-
livery. A binary terminological distinction of “Static” versus “Dy-
namic” methods is commonly used, based on the understand-
ing that barrier phenotypes are induced and maintained by, not
only, a) the cellular contacts made by EC with other cells of the
NVU, notably pericytes/vascular smooth muscle cells and astro-
cytes, but also, b) the shear forces imparted by circulating plasma
on ECs. Three main categories of in vitro model are encountered
(Figure 10), as follows:
The two main “Static” models (without fluid flow) comprise:
a) Transwell—a suspended semipermeable platform on which
an endothelial monolayer is grown and b) Spheroid—a multi-
cellular organoid of brain cells enveloped in endothelia, while c)
“Dynamic in vitro (DIV) models” include those of sub-millimeter
lumen diameter, but more recently their smaller iteration, hence
the term microfluidic devices. These comprise synthetic scaffolds
enabling organotypic growth of cells into perfusable microvascu-
lature networks, also termed “organ-on-a-chip.”[328]
5.1. Transwell Models of the BBB
Transwell methods have become the most commonly used and
convenient in vitro approach.[329–333] They involve the suspension
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Figure 10. Outlines of three types of in vitro BBB models currently available.
of a permeable platform as an insert into wells of multiwell plates.
ECs are grown on the matrix-coated (collagen/fibronectin) sur-
face of the insert to form a monolayer that is suspended above
the base plastic of the well, giving access to two compartments:
luminal, drug delivery site (inside the insert) and abluminal (be-
neath the insert) equivalent to the tissue parenchyma.
5.1.1. Monoculture of Endothelium on Transwell Inserts
For convenience, ease of tissue sourcing and robust barrier prop-
erties, porcine or bovine brain EC (PBEC) monolayers are an im-
pressive option.[334] When grown in monolayers, primary PBEC
can achieve trans-endothelial electrical resistance (TEER) of 800
Ωcm2 within 24 h, a functional measure of paracellular junc-
tional tightness.[334] They can also be cocultured with astrocytes
to enhance expression of other barrier features, such as receptor-
mediated transcytosis.
There is support for the validity of transwell animal models of
the BBB. Heymans et al. have compared the in vitro and in vivo
permeability of a panel of 27 CNS drugs having a wide range
of physiochemical properties and classified by properties such
as: a) their binding to brain tissue (fraction unbound to brain,
fu,br, the ratio of drug in interstitial fluid/total in brain) and b)
their lipophilicity (LogP).[335] These authors used two alternative
in vitro bovine BBB models[336] and correlated drug permeabili-
ties in these with published data from an in vitro method of rat
in situ brain perfusion, employing the same drugs.[337]
The two alternative in vitro transwell BBB models used pri-
mary bovine BCECs grown on transwell semi-permeable inserts
as a monolayer, either a) in monoculture, else b) in quadruple co-
culture with mixed primary glial cells grown in the well to which
the monolayer insert was placed. Glia were mixed in the follow-
ing proportions of cells that could be identified/followed by cell-
specific immune-fluorescent markers: 60% glial fibrillary acidic
protein positive astrocytes, 30% O4 positive oligodendrocytes and
10% ED-1 positive microglia. The latter better modeled not only
permeability across the BBB but also the binding kinetics of drug
to brain tissue.[335]
Alternative calculations of in vitro brain permeability were
made: 1) Apparent permeability coefficient (Papp) which was de-
fined as the rate of flux/appearance of compounds in the ablumi-
nal well (receiver) compartment 30 min following initial delivery
into the luminal insert (donor) compartment. 2) Endothelial per-
meability (Pe) was calculated by the method of cylindrical pore
theory, involving average cumulative clearance of drug over time
to determine the permeability surface area product of the filter
alone and that of the filter with endothelia. The difference being
divided by surface area of the filter insert to give Pe.[335]
Good correlation between in vitro and in vivo drug permeabil-
ity was reported,[335] suggesting the in vitro BBB model to be pre-
dictive of in vivo rate of brain penetration for those CNS com-
pounds used; but that the correlation was best when the Pe cal-
culation of in vitro permeability was used. Also, modeling dis-
crepancies for drugs having a low fraction unbound to brain (fu,br)
were resolved when using the coculture method, consistent with
the hypothesis that the presence of glial cells in the abluminal
compartment better mimicked the effect of brain tissue binding
that occurs in vivo.
5.1.2. Multiculture of Neurovascular Cells in Transwell, Using
Primary, Immortalized, or “Renewable” Stem (Isolated or Induced)
Human Cells
Though regarded as a valuable species comparison with human
physiology, the favorable barrier properties that can be achieved
when using bovine or porcine endothelia in transwell are not
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readily duplicated using human cells without more complexity
of coculture conditions. Human tissues are also not as readily
available as animal. Nevertheless, renewable human cells include
hematopoietic stem cells from umbilical cord blood,[338] circulat-
ing endothelial progenitors mobilized from bone marrow[339] and
induced pluripotent stem cells[340,341] (hiPS, e.g., the lines IMR90-
4 and ARiPS). These can be differentiated into somatic cell types,
thereby offering a virtually unlimited cell source with which to
model BBB in vitro.
Appelt-Menzel et al. have compared the effects of the combi-
nation of different cell types in bi-, tri- and quadruple coculture
in transwell on the barrier properties of human EC derived from
hiPS.[342] They obtained five human cell types: i) primary fetal
brain pericytes, ii) fetal NSC as well as induced pluripotent stem
cells (hiPS) induced to differentiate into iii) NSC, iv) ECs, and
v) astrocytes using methods derived from previous works.[343,344]
Treatment of EC grown in monolayer on transwell inserts with
10 × 10−6 m RA was used to enhance their barrier properties.[345]
Transwell coculture is limited in that it simulates “indirect, hu-
moral, noncontact” effects of associated brain cell types on BBB
EC integrity. Transwell cocultures may simulate only the humoral
interactions between cells associated with the BBB, even if cocul-
tured cells are plated on the abluminal surface, below ECs on the
luminal surface of the insert. Nevertheless, Appelt-Menzel et al.
investigated the beneficial effects of combination of ECs in bi-,
tri-, and quadruple cocultures with pericytes, astrocytes and
NSCs in transwell. hiPS-derived ECs were grown on the lumi-
nal transwell inserts while all other cells were plated, not in di-
rect contact with ECs, but within the well base, i.e., not upon
the abluminal surface of the transwell. This facilitated uptake
assays, since absorbance by cell types other than ECs could be
avoided.[342] Although this format does not fully replicate the
direct cellular contacts found in 3D spheroid organoids or mi-
crofluidic organoids (subsequent sections) it has experimental
benefits.
The barrier properties of hiPS-derived ECs obtained were vali-
dated by their expression of EC markers such as von Willebrand
factor (vWF), TJ associated protein (ZO-1), and the GLUT-1; also
the adherence junction protein, vascular endothelial cadherin
(CDH5); though there was weaker expression of the endothelial
proteins angiopoietin receptor 2 (TIE2) and PECAM1 (CD31).[342]
EC also expressed BBB transporters and TJ proteins (the P-gp ef-
flux transporter, ABCB1 (efflux transporter), the SLC1A1 (gluta-
mate transporter), SLC2A1 (glucose transporter), and OCLN (oc-
cludin)). An uptake assay with fluorescein isothiocyanate FITC-
labeled acetylated low-density lipoprotein also indicated lower ac-
cumulation compared to human umbilical vein endothelial cell
monolayer as control.[342]
Electrical resistance has been measured up to 5900 Ωcm2 in
vivo, across the BBB in anaesthetized rats.[346] The TEER of triple
cocultures of hCMEC/D3 in transwell has been reported as only
≈50 Ωcm2.[347] This is comparable to other studies of immortal-
ized human ECs in transwell, suggesting that the electrical re-
sistance of human endothelia is low compared to other species,
notably including murine, bovine and porcine. However, in the
study by Appelt-Menzel et al. using human cells, the mean TEER
for the EC monolayer itself, and all nine cocultures in bi, tri, and
quadruple combinations of human cells in vitro, were greater
than 1000 Ωcm2, indicating tightness of cellular junctions lim-
iting paracellular permeability that can be achieved in transwell
systems.[342]
The effect of coculture was to significantly increase TEER com-
pared with hiPS-EC monolayers (1198 ± 265 Ω cm2) for both tri-
culture of EC with hiPS-NSC and primary human pericytes (1723
± 90 Ω cm2) or quadruple coculture with hiPS-NSC, astrocytes
and primary human pericytes (1757 ± 320 Ω cm2).[342] The ex-
pressions of transporters (ABCB1, SLC1A1, SLC2A1) and the TJ
component occludin were on average upregulated by 1.5-fold fol-
lowing quadruple culture, but statistical significance was reached
only for SLC2A1.[342]
Investigation of drug transport via transcellular routes re-
vealed that compared to EC in monocultures, quadruple cultures
significantly decreased permeability to caffeine, a marker of fast
transcellular trafficking.[342]
Appelt-Menzel et al. illustrated the utility of transwell endothe-
lial monolayers for in vitro simulation of human BBB. EC bar-
rier properties were augmented by retinoic acid (RA)-dependent
differentiation from hiPCs, and while kept from making direct
contacts with EC, indirect mediation from coculture with tri-
and quadruple combinations of pericytes or astrocytes and NSCs
promoted barrier expression.[342] Although the transwell method
does not model the possible effects of fluidic phenomena and
direct cellular contacts, it provides a robust validation that re-
newable human in vitro BBB modeling can be achieved by this
“static” in vitro system. Moreover, the utility of the transwell
method is suggested by its popularity.
5.2. Spheroids—Multicellular Neurovascular Spherical
Organoids as In Vitro BBB Models
To validate a relatively new in vitro system, Cho et al. have com-
pared the barrier characteristics of triple coculture of the same
cells in transwell with self-assembling multicellular organoids
(spheroids).[347] To form spheroids the following cell types were
combined in triple coculture on low attachment plates, coated
with soft agarose, in 1:1:1 ratio,[347,348] but with the omission of
VEGF-A supplement, known to reduce paracellular barrier in-
tegrity:
• Primary human astrocytes (phAC)
• Primary human brain vascular pericytes (pHBVP) and
• Either a) primary human brain microvascular EC (phBMVEC)
or b) an immortalized human cerebral microvascular EC line
D3 (hCMEC/D3).
Cells formed compact spheroids within 12 h, with average suc-
cess rate of 90% based on physical characteristics. Spheroids re-
mained stable and viable over 17 days. After 48 h coculture, strat-
ification of cells were made using fluorescence dyes (cell tracker
dyes). After 48 h coculture, stratification of cells were made us-
ing fluorescence dyes (cell tracker dyes). The cells were fluores-
cently labeled for long-term tracing of living cells. The spheroids
were imaged in confocal laser scanning microscopy.[348] Astro-
cytes occupied the spheroid core while ECs together with peri-
cytes formed a surface monolayer, mimicking the in vivo organi-
zation of these cells. Consistent with the anatomical formation of
a paracellular barrier, expression of TJ proteins (occludin, claudin
5 and ZO-1) was observed at the surface of spheroids.
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In terms of functional properties, the surfaces of spheroids
established with either primary or immortalized ECs exhib-
ited low permeability to high molecular weight TRITC-dextran
(155 kDa).[347] The paracellular permeability of spheroids to
TRITC-dextran (10 mg mL−1) was responsive to the agonist
VEGF-A, which was shown to affect paracellular permeability
by disrupting ZO-1 staining. Exclusion transport appeared in-
tact/active in spheroids, since treatment with an inhibitor of P-
gp efflux (LY335979)[347] significantly increased the influx of the
fluorescent substrate rhodamine 123 (Rho 123) into spheroids.
In this work, active transport of fluorescently labeled (Cy5.5
or TRITC) brain penetrant agent angiopep-2 via RMT through
the LRP-1 was demonstrated by optical sectioning of spheroids
in confocal microscopy. Penetration to 100 µm was signifi-
cantly greater for angiopep-2 than for a scrambled sequence
of amino acids in spheroids prepared from either hBMVECs
or hCMEC/D3 cells. That spheroids remained completely im-
permeant to TRITC-dextran (155 kDa; 10 µg mL−1) suggested
receptor mediated transport rather than nonspecific permeabi-
lization. Further, angiopep-2 accumulation by spheroids was in-
habitable when incubated at 4 °C. Fluorescence microscopy of
frozen section confirmed angiopep-2 in the spheroid core. Deliv-
ery of angiopep-2 conjugates of various sizes (6, 8, and 30 kDa)
to the spheroid core was observed using tetramethylrhodamine
(TAMRA) labeling. This spheroid model therefore demonstrates
the potential of angiopep-2 to act as a vehicle to facilitate drug
permeation across the BBB.
Since most drugs are not fluorescent, their transit is diffi-
cult to follow. Unlike the aqueous superfusing compartments
of transwells that are conveniently sampled, making them
amenable to chemical analysis, including high performance
chromatography,[349] to verify drug transit, the monitoring of
drug movements into spheroids is more difficult. A novel
method, matrix-assisted laser desorption/ionization mass spec-
trometry imaging (MALDI-MSI) has therefore been applied at
a spatial resolution of 30 µm in frozen section of spheroids
(avg. diameter ≈300 µm) to confirm the penetration of BKM120
(a BBB-penetrant control)[347,350] versus no detectable signal of
dabrafenib (BBB-impenetrant control). Penetration occurred in
the presence of no increase in TRITC, confirming paracellular
integrity.
5.2.1. Validation of Spheroids as Models of Pathology and
Toxicological Insult
In an effort to recapitulate the full range and proportionate com-
plement of cells found in vivo, Nzou et al. combined the six major
types present within human brain cortex in an in vitro spheroid
model of the BBB. Organoids (spheroids) were prepared by the
hanging drop method (rather than low adherence substrate) re-
lying on the self-assembly of cells. They determined that com-
bining cells en masse (altogether) was less effective at creating a
contiguous endothelial surface coat than a two-stage process; first
growing a central core of astrocytes and neurones prior to coat-
ing with endothelia/pericytes.[351] The cells used were either 1)
primary human brain microvascular endothelial cells (HBMEC);
2) pHBVP, and the following derived from hiPSC: 3) human as-
trocytes (HA); 4) human microglia (HM); 5) human oligodendro-
cytes (HO), and 6) human neurones (HN). Cells were expanded
before being harvested and then combined as explained in the
following.
In preliminary experiments, 3-cell (HBMEC, HP, HA) and 4-
cell organoids were made using primary HBMEC, HP, HA, and
HCN-2 (the ATCC cell line: homosapiens cortical neurones-2)
prelabeled with a long-term tracker dye, in the ratio of 1:1:5:6.
These were allowed to mature for 96 h before being placed
individually into 96 well plates for use. That incomplete bar-
rier properties were obtained was demonstrated by FITC-labeled
IgG being visualized at the spheroid core, though labeling was
less than following paracellular permeabilization by histamine
treatment.[351]
In order to prepare 6-cell organoids a staged method was used.
This overcame incomplete EC coverage that occurred without.
Cells were combined in the ratio of 30% HBMEC, 15% pHBVP,
15% HA, 5% HM, 15% HO, and 20% HN. First, neuronal-glial
organoids containing HA, HM, HO, and HN were allowed to
preform for 48 h before subsequent inclusion of rat tail colla-
gen I, HBMEC and pHBVP to grow an encapsulating layer about
the preformed neural–glial organoid. Individual 6-cell organoids
were matured for a further 48 h in 96 well plates and remained
viable for at least 6–10 days.[351]
These organoids expressed transcellular markers (P-gp and
GLUT-1) as well as paracellular markers (of TJs: ZO-1 and
claudin-5, and adherens markers: VE-cadherin and beta-catenin).
Furthermore, the utility of the 2-stage, 6-cell organoids to toxico-
logical and pathological models was validated in the following
three scenarios:[351]
• Permeabilization response to hypoxia of endothelia-enveloped
organoids, modeling stroke pathology.
• Resistance of endothelia-enveloped organoids to Hg2+ toxic-
ity, modeling heavy metal poisoning.
• Susceptibility and resistance of endothelia-enveloped
organoids to MPTP/MPP+ toxicity, modeling neurotoxin-
induced Parkinson’s disease.
5.2.2. Permeabilization of In Vitro Organoid BBB by Hypoxia,
Modeling Stroke
Hypoxia is a driver of neurological injury associated with stroke,
and has been shown to induce permeability changes in a tran-
swell model of cerebral BBB.[352] Exposure of 6-cell organoids to
24 h hypoxia (0.1% O2) at day 6 of culture appeared to disrupt the
expression of markers of paracellular barrier function (claudin-5,
ZO-1, beta-catenin and VE-cadherin) and was confirmed to bring
about a statistically significant reduction in relative staining of
two (beta-catenin and VE-cadherin). This organoid model may
therefore be of use in modeling the pathology of response to bar-
rier disruption during stroke.
5.2.3. Selective Movement of Inorganic Mercury across In Vitro
Organoid BBB, Modeling the Neurotoxicity of Heavy Metal
Poisoning
Antioxidant systems of the brain depend upon selenoenzymes.
Mercury poisoning involves their irreversible inhibition by
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sequestration of selenium. Because of their positive charge, mer-
cury II salts are hydrophilic, highly soluble and do not cross the
intact paracellular barrier. The susceptibility of glia and neurones
of spheroids to mercury toxicity was used to validate the charge
selectivity of the barrier function of covering endothelia.[351] Bar-
rier functions of organoids made entirely from neurones, there-
fore lacking an endothelial barrier layer (BBB−), were compared
with 6-cell stage-assembled organoids having an endothelial bar-
rier (BBB+). Assessment of their susceptibility to poisoning by
mercury II chloride was made using ATP production as a mea-
sure of cell viability. Consistent with a lowered permeability of
Hg2+ through an intact endothelial barrier (BBB+), neuronal
organoids that lacked an endothelial barrier (BBB−) demon-
strated significantly higher cell death, measured by reduced ATP
production. That ATP production significantly increased in BBB+
organoids exposed to mercury II chloride, is consistent with el-
evated demand for Na-K-ATPase activity[353] to sustain facilitated
export of ions. That ATP production in BBB+ organoids exposed
to mercury II chloride was dependent on barrier activity was con-
firmed by permeabilizing with histamine, which lowered ATP
production, indicating penetration of mercury.
5.2.4. Neurotoxicity of MPTP in 6-Cell, Stage-Assembled Organoids
In vivo, the lipophilic small molecule prodrug 1-methyl-4-pheynl-
1,2,3,6-tetrahydropyridine (MPTP) is known to be enzymatically
converted by monoaminoxidase-B (MOAB) of glial cells to form
the neurotoxic metabolite 1-methyl-4-phenylpyridinium (MPP+),
which depletes dopaminergic neurones to model drug-induced
PD. In the in vitro BBB+ model, MPTP was shown to cross
the 6-cell, stage-assembled organoids due to its lipophilicity,
was converted to MPP+ by glia and caused a reduction in ATP
production/viability.[351] In contrast, ATP production of neuronal
organoids lacking the endothelial envelope (BBB−) were unaf-
fected. Conversely, MPP+ was toxic to BBB− neuronal organoids,
reducing ATP production, but BBB+ organoids were impervious
to the hydrophilic compound. The selective resistance to MPP+
of BBB+ organoids was dependent upon barrier activity. This was
demonstrated by the permeabilization of endothelial barrier in
response to histamine treatment, which caused a significant fall
in ATP production/viability. Taken together, these results confirm
the utility of in vitro 6-cell, stage-assembled organoids in model-
ing relevant pathological and toxicological challenges to the BBB.
5.3. Dynamic In Vitro Models—Microfluidic Vascular Networks
DIV models of the BBB achieve media flow through an artifi-
cial capillary-like structure.[325,354,327] Hollow fibers incorporating
channels and made from gas-permeable silicone tubing are used
to create a frame onto which cocultures are seeded and grown:
Intraluminal surfaces are lined by ECs; accessory cells (pericytes
and astrocytes) are grown abluminally.[354,327] The self-assembly
of mixtures of cells on flat, optically accessible forms, perfused
by the peristaltic pumping of media recreates vasculogenic con-
ditions, which result in networks of patent circular vessels resem-
bling capillaries in vitro. Physiologically relevant pulsatile pump-
ing of media replicates circulatory activity in the formation and
maintenance of vessel architectures and barrier integrity.[325] DIV
models thereby provide not only the cellular interactions of ECs
with accessory cells (particularly PEs and astrocytes) but also the
shear force derived from fluid flows. These are two important
stimuli known independently to maintain barrier phenotype.
Campisi et al. recently created the first capillary-like vascu-
lar structures by self-assembly incorporating three human cell
types (iPSC-EC combined with primary brain pericytes and astro-
cytes) cocultured in a 3D cast created using a polydimethylsilox-
ane (PDMS; Sylgard) based soft lithography technique.[325] The
chip was accessible to confocal fluorescence assay, while lysis of
cells was achievable for biochemical/expression assay. The geo-
metric architecture of the micro-vasculature networks obtained
was visible under glass and characterized by confocal imaging in
terms of a) lateral and transverse vessel diameters, b) percent-
age of image area containing vessels, and c) total branch length.
Direct physical contacts of pericytes and astrocytes developed in
vitro, resembling the in vivo situation. Contact with pericytes or
the conditioned medium of pericytes promoted smaller, more
rounded and highly branched vessels than iPSC-ECs in mono-
culture, and this interconnected and branched architecture was
further enhanced by tri-culture with astrocytes. While the over-
all transverse diameters were similar in all conditions (≈30 µm)
lateral vessel diameters were successively reduced compared with
iPSC-ECs in monoculture (108 µm) by co- (64 µm) and tri-culture
(42 µm); tending toward greater circularity in tri-culture com-
pared with more elliptical vessel shapes in monoculture. Like-
wise, average branch length decreased from monoculture (266 ±
40 µm) to coculture (179 ± 31 µm) to tri-culture (136 ± 24 µm).
Vascular networks were more connected, narrower and covered
less area, more similar to in vitro vessel morphology.[325]
Consistent with improved barrier functions in the tri-cultures,
immunocytochemical and mRNA expressions of ECM proteins
(laminin and collagen IV) and junction proteins (ZO-1, occludin
and caudin-5) were increased. Permeability coefficients were
measured by introducing fluorescently labeled dextran tracers
and capturing confocal images at 5 min intervals. The permeabil-
ity of 40 kDa FITC-dextran decreased progressively under mono-,
co and tri-culture (6.6; 2.5 and 0.89 × 10−7 cm s−1, respectively). A
similar trend was observed with 10 kDa FITC-dextran. Moreover,
permeabilities of this model were reportedly lower than other
previously published microfluidic models.[325]
The resemblance to in vitro properties of microvascular as-
semblies derived from this method compared with static models
was suggested. Various applications are proposed for such mi-
crofluidic models, including not only the assay of BBB perme-
ability to fluorescently labeled therapeutic nanocarriers,[354] but
also the investigation of vascular interaction with inflammatory
cells that occurs in neurodegenerative disease, or metastatic can-
cer extravasation in this promising model.
5.4. Comparing In vitro BBB Methods
In vitro simulations of the BBB aim to inform the potential for
pharmaceutical success of drug candidates for neurological dis-
orders. The same models also offer a means to advance our un-
derstanding of physiological mechanisms and pathological pro-
cesses of the brain.
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Current in vitro methods are far from a perfect facsimile of
the BBB in vivo, but our review illustrates ongoing advances in
alternative techniques. The most widely used model (endothe-
lia as monolayers on transwell inserts) is notable for the ease
with which luminal and abluminal compartments can be sam-
pled, that TEER can be measured, and the facility with which
high paracellular barrier properties from experimental animal
(e.g., porcine) monolayers can be obtained. While the derivation
of cells from renewable sources (hiPSCs), grown in RA, without
VEGF-A supplementation and in coculture with associated cells
(astrocytes, pericytes, glia and neuronal cells) are each ways to
improve the paracellular barrier properties and the expressions
of transcellular transporters of human in vitro BBB models.[342]
Moreover, cocultures serve to mimic not only the pharmacoki-
netic properties of a) endothelial permeability but also b) the frac-
tion of drug bound to brain tissue (fu,br) and as such give better
correlations between transwell in vitro models and in vivo data on
the permeation and tissue binding of a range of drug types.[335]
Although less established, in vitro spheroid BBB models are
simple and reliably grown. The use of hiPSC derived cells for
self-assembly into minimally the 3-cell organoids, or ideally from
6-cells known to be involved in the NVU. Nzou et al. provides a
renewable model, where the direct contact of cell types present in
vitro is recapitulated.[351] Moreover, organoids simulate endothe-
lial permeability as well as drug binding to brain tissue. Because
organoids are conglomerates of cells, they do not have the same
facility of transwell for sampling of luminal and abluminal com-
partments or measuring TEER. However, fluorescently labeled
drugs may be followed in spheroids using confocal slice imaging
(readily available), else resolution of unlabeled drugs may be re-
solved to 30 µm within frozen sections by MALDI-MSI[347] if the
technique is available. Spheroids better model the direct physical
association of cells, albeit in an “inside-out” topology of the NVU,
bettered in this respect only by more complex and less widely
used fluidic “capillary-like” models. Already, spheroids have been
rated favorably when compared with transwell models,[347] and
are proposed as the next generation of high throughput screen-
ing for BBB-penetrant drug candidates, as well as to model BBB
properties associated with stroke, degenerative or toxicological
neurological disorders.[351]
Developments in DIV models have benefited significantly
from technological advances in printing manufacture, which
have supported reduction in vessel size, a network complexity
resembling that in vivo and achieving microfluidic devices ac-
cessible to optical and molecular assay.[354] There is also poten-
tial to incorporate fluid flow into versions of existing static mod-
els, particularly for spheroids. However, fluidic methods are not
as widespread or established as to yet obtain the convenience of
transwell, which are readily available as commercial kits (e.g.,
RBT-24H, BBB Kit).[355] Table 6 summarizes the pros and cons
of the different presented BBB models.
6. Interactions of Nanocarriers with the
Complement System
Investigators should evaluate the risks and benefits of the for-
mulations before starting clinical trials. A clinical trial may be
justified when the benefits of a formulation are greater than the
risks.[356] Most of the brain-targeting nanoparticle formulations
are designed to be injected intravenously. Therefore, these for-
mulations should show blood compatibility, nontoxicity, and no
immunogenicity to minimize risks to the patients. Consequently,
Sections 6 and 7 cover these aspects of the formulations.
The complement system is one of the most critical compo-
nents of innate immune responses that have evolved to protect
the host from invading pathogens like bacteria and viruses, and
also to eliminate any foreign materials that enter the body.[357,358]
The complement system has the ability to distinguish “self” from
“nonself”/“foreign” material and to eliminate or neutralize them.
Contact with a “foreign” material or an invading pathogen results
in the activation of the complement system. Depending on the
nature of the trigger, the ensuing complement activation may cas-
cade via one of the three distinct pathways namely a) the classical
pathway, b) the alternative pathway (AP), and c) the lectin path-
way (LP) (Figure 11).
The classical pathway is activated by immune complexes that
are formed on pathogen surfaces leading to C1 complex forma-
tion while the mannan-binding lectin (MBL) pathway recognizes
mannose-terminating glycans on pathogens.[357] The binding of
MBL to carbohydrates on the pathogen surface activates MBL-
associated serine proteases (MASPs).[359] The MBL-MASP com-
plexes activate C3 directly or generate C3 convertase. Essentially,
the activation of both classical and LPs result in the formation of
highly reactive C3b that binds to hydroxyls and amines on foreign
surfaces forming a membrane pore complex C5b-9 and potent
anaphylatoxins C3a and C5a.[360] In the AP, a permanent low-
level activation of C3 by spontaneous hydrolysis of a thiolester
leads to production of C3 (H2O).
Due to the lack of natural complement regulators factor H
(FH) and factor I on pathogen surface, alternative activation of C3
convertase C3bBb occurs. C3 convertase cleaves C3 into C3a (ana-
phylatoxins) and C3b (opsonin). Complement activation leads to
a multitude of responses that include deposition of C3 fragments
(C3b) on the surface of the pathogen (opsonization) which in turn
leads to phagocytosis, formation of the membrane-damaging
C5b-9 complex which effectively induces bacterial lysis, release
of complement peptides C3a, C4a and C5a (referred to as ana-
phylatoxins) that mediate recruitment of immune cells result-
ing in inflammation and activation of epithelial, endothelial cells
and platelets.[357,361] Uncontrolled release of anaphylatoxins may
promote life threatening inflammatory reactions that may lead
to severe cardio-respiratory distress and even cardiac arrest and
death.[362]
6.1. Nanoparticles and the Complement System
Because NCs are largely man-made synthetic structures, they
are typically recognized by the host immune system as “foreign”
and evoke complement activation. NP-induced complement ac-
tivation has been reported with a variety of NCs including gold
and silver NPs,[19] SPIONs,[363] polymer NCs,[20] liposomes,[21]
micelles,[364] CNTs,[365] graphene,[366] and dendrimers.[367] In the
following sections the activation of the complement system is dis-
cussed when NPs are administered i.v., however, the brain also
has the complement system, which can be activated by nanosize
objects such as A𝛽 plaques.[368] This leads to attraction and acti-
vation of glial cells, which under such activation conditions, can
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Table 6. Comparative features of in vitro models different BBB models.
Preclinical development of CNS drug targets in human diseases involves complementary in vitro modeling methods. Summary advantages and disadvantages of variants of
these models of the BBB are herein reviewed.
Advantages Disadvantages
In vivo + Animal models are considered the gold standard of
preclinical predictive tools, but ≈80% of drug
candidates identified in this way later fail in clinical
trial
– Animal models are analogous in many of the cell, molecular, organ
system functions and connections found in man, but may not
accurately reflect the human condition
– Relatively low throughput, expensive, and limited by ethical
considerations
In vitro: static (transwell and organoid)
+ Includes the barrier phenotypes induced by cellular
contacts of EC with a basement membrane, each
other, and if included in coculture various other cells
of the NVU, notably pericytes/vascular smooth
muscle cells and astrocytes
– Omits the barrier phenotypes that are induced and maintained by the
shear forces imparted by circulating plasma on ECs
Transwell A suspended semi-permeable platform on which endothelial monolayer grown; with or without cocultured cells on abluminal surface or
on base of well into which insert placed
Monolayer (transwell) + Commonly used (body of comparative work is
available)
+ Convenience of treatment and sampling of luminal
and abluminal compartments; ease of tissue
sourcing
+ Robust barrier properties of animal (porcine or
bovine) brain EC monolayers are an impressive
option
– Human monolayers have poor barrier properties by comparison
– Omit the cellular contacts made by EC with other cells of the NVU,
notably pericytes/vascular smooth muscle cells and astrocytes that
determine barrier phenotype
– Omits the barrier phenotypes that are induced and maintained by the
shear forces imparted by circulating plasma on ECs
CO-/multi-culture (transwell) + Can achieve good correlation between in vitro and in
vivo drug permeability, validating predictive value,
but cellular composition critical: Presence of
cocultured glial cells in the abluminal compartment
better mimicked the effect of brain tissue binding
that occurs in vivo
– Omits direct cellular contacts that induce barrier properties (that are
present in 3D spheroid organoids or microfluidic organoids); also,
does not mimic shear forces of fluidic systems
Multi-culture variants (primary, immortalized, and renewable stem cells)
Features relevant to all in vitro platforms—transwell, organoid, and organ-on-a-chip
• Primary cells + Differentiated phenotype; clinically relevant if human – Difficult to source human cells.
– Brief use (limited growth)
• Immortalized (cell lines) + Convenience of renewable cells; of which
commercial banks available
Lack of polarization–differentiation state might not reflect normal
Generally, well characterized, but susceptible to genetic changes over
multiple passages
• Renewable stem cells + Renewable, sustainably available (cells can be
frozen/grown up)
+ Human cells are “induced,” not requiring placental
material
+ Can avoid immunogenic mismatch if all cells derived
from same progenitor
+ Self-aggregating, thought to recapitulate cues for
development of barrier phenotype







+ Relatively new model, but now established and
becoming validated
+ Available in variants of complexity, using primary,
immortalized or “renewable” stem (isolated or
induced) human cells
+ Includes the barrier phenotypes induced by direct
cellular contacts
– Omits the barrier phenotypes induced and maintained by shear forces
Dynamic in vitro models
(“organ-on-a-chip”)
+ The fullest representation of the complex cellular
and shear force interactions that establish and
sustain barrier properties
– Relatively low throughput
In silico +/- Models involve computation based on
physiochemical and physiological parameters
derived from/requiring validation by in vivo/in
vitro studies
+/- Provide leads; need validation
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Figure 11. Complement activation. Complement system is composed of three different pathways. The classical pathway (CP) is activated by immune
complex formation on pathogen surface and by calreticulin expressed on apoptotic cells, leading to C1 complex association. The LP recognizes mannose-
terminating glycan on pathogens leading to MBL MASP complex activation. Both induce formation of the classical C3 convertases C4b2b. The AP is
permanently activated at low level by spontaneous hydrolysis of C3 into C3 (H2O). Lack of complement inhibitor on pathogens induces alternative
C3 convertase activation C3bBb. Complement activation leads to opsonization and phagocytosis by C3b deposition, bacterial lysis by C5b–9 complex
formation and inflammation by recruitment of immune cells, endothelial and epithelial cell activation, and platelet activation. Membrane cofactor protein
(MCP), decay accelerating factor (DAF), complement receptor 1 (CR1), and C4 binding protein (C4BP) inhibit the complement activation by the classical
pathway. DAF, MCP, CR1, and Factor H inhibit the complement activation by the AP.
produce neurotoxic substances. Therefore, the complement ac-
tivation also should be taken into consideration, when NPs are
delivered intracerebrally. Then in this article, it is presumed NPs
that activate the complement system in the blood, would also ac-
tivate the complement system in the brain.
6.2. Nanoparticle-Induced Complement Activation-Related
Pseudoallergy (CARPA)
Activation of immune cells with the consequent production
of anaphylatoxins and cytokines can sometimes result in se-
vere and immediate hypersensitivity reactions with symptoms
and signs of anaphylaxis such as chills, rigors, facial flush-
ing, facial swelling, headaches and cardiorespiratory distress.[369]
Since this reaction is not a true IgE mediated hypersensi-
tivity reaction, Szebeni coined the term Complement Activa-
tion Related Pseudoallergy or CARPA to distinguish it from
the Type I IgE-mediated hypersensitivity reactions.[369] CARPA
is a well-documented adverse reaction associated with a vari-
ety of nanopharmaceuticals including Doxil (liposomal doxoru-
bicin), Ambisome (liposomal amphotericin), Taxol (cremophore-
paclitaxel), Sandimmune (cremophore-cyclosporine A) and Fer-
ridex (SPIONs).[369–372] The pathogenesis of CARPA is thought
to be due to the anaphylatoxins (C3a and C5a) and other C3 frag-
ments such as C3d.[373] The generated anaphylatoxins bind to
their receptors on the immune cells such as macrophages, mast
cells and basophils and trigger the release of various vasoactive
substances including histamine, leukotrienes, platelet activating
factor, prostaglandins and thromboxane A2. Although CARPA
has proved fatal in some cases, it can often be treated with an-
tihistamines, corticosteroids and epinephrine.[374] It may also be
possible to prevent CARPA by the pre-administration of comple-
ment inhibitors such as indomethacin or desensitization using
empty liposomes.[375]
6.3. Complement-Mediated Clearance of Nanoparticles
The complement system plays a major role in clearing nanomate-
rials from the circulation. As outlined in the preceding sections,
NPs, upon entering the circulation, activate the complement sys-
tem. The activation of the complement system leads to the gen-
eration and deposition of opsonins such as C3b on the surface of
the NPs (opsonization). The opsonized NPs are rapidly engulfed
by the cells of the RES (e.g., macrophages) that express comple-
ment receptors.
In addition, NPs can also be recognized and taken up by
various blood cells. Neutrophils express complement receptors
C1qR, CR1, CR3, and CR4 that are involved in phagocytosis of
bacteria,[376] while lymphocytes express complement receptors
CR2 and CR1.[377] Monocytes are known to uptake NPs. Platelets
have been shown to bind to C3b via glycoprotein IIb/IIIa.[378] Ler-
oux et al. demonstrated that poly(d,l-lactic acid) NPs are internal-
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ized by monocytes and macrophages.[379] Inturi et al. have shown
that iron oxide NPs are recognized by leucocytes and platelets
via complement C3 and engulfed. They have also shown that
the uptake of iron oxide NPs by leucocytes can be prevented
by inhibitors of the AP of the complement system such as an-
tiproperdin antibody.[380] The role of neutrophils in the uptake of
biodegradable NPs was demonstrated by Zambaux et al.[381]
6.4. Influence of Nanoparticle Characteristics on
Nanoparticle-Induced Complement Activation
Several intrinsic properties of nanomaterials such as the com-
position, size, shape, surface charge and surface characteris-
tics/modifications, are known to influence the nature and the
magnitude of NP induced complement activation.
6.4.1. Nanomaterial Composition
The impact of nanomaterial composition on the complement ac-
tivation is particularly noticeable in lipid NCs (e.g., liposomes,
micelles) and polymer NPs. For instance, the chain length and
architecture (e.g., linear or branched) of polymer NPs can af-
fect the interaction between the nanomaterial and the com-
plement system. Furthermore, the chemical make-up of the
polymer (e.g., hydrophobicity/hydrophilicity) and the types of
functional groups also influence complement activation.[382] Hu-
lander et al. studied the potential of various noble metal NPs
and Bactiguard, which is a composite material, to generate
complement factor 3 fragment (C3a). Their study showed that
the C3a generation potential varied among the noble metal
NPs (silver>gold>palladium>Bactiguard>titanium).[383] Wibroe
et al. examined the effect of graphene oxide (GO) form (in solu-
tion versus immobilized) and oxidation state on the complement
system in human blood. In solution, there was a decrease in GO-
mediated complement activation with decreasing surface oxygen
content, whereas with immobilized GO complement response
was reversed and increased with decreasing oxygen content.[366]
6.4.2. Particle Size
The size of NPs plays an important role in complement activa-
tion. Pedersen et al. investigated the importance of the curvature
of the NP in complement activation using dextran-coated NPs of
different sizes (250 and 600 nm) and human IgM antibodies to
dextran. Interestingly, potent antibody-mediated complement ac-
tivation was noted on 250 nm sized NPs whereas 600 nm particles
were less potent activators.[384]
Pham et al. investigated the effect of particle characteris-
tics including the size and polydispersity on nanomaterial-
induced complement activation using a metric called “Residual
Hemolytic Activity” (RHA) for perfluorocarbon NPs of varying
size, charge and surface chemistry. Subsequently, the researchers
analyzed the above data using a decision tree learning algorithm
to determine the effect of certain NP characteristics on com-
plement activation.[385] The authors claim that physicochemical
properties of NPs (size, zeta potential, and polydispersity index
(PdI)) can serve as good predictors of NP-dependent complement
activation.[386] This study predicted that reducing the particle size
would reduce the chance of complement activation. For example,
NPs with the size of 204.55 nm were low complement activator
(being safe), while increasing the particle size to 259.4 nm (main-
taining the same zeta potential) turned the NPs to a highly acti-
vating complement formulation.
6.4.3. Surface Charge
Surface charge has been shown to play a role in NP-mediated
complement activation. Several studies have shown that charged
nanomaterials are more efficient activators of the complement
system compared to their neutral counterparts.[387] This obser-
vation has been made with a variety of nanomaterials includ-
ing polypropylene sulfide NPs, lipid nanocapsules, cyclodextrin-
containing polycation based NPs and polystyrene nanospheres.
Both positively charged and negatively charged NPs have been
shown to activate the complement system. The study carried
out by Szebeni and co-workers investigated CARPA in a porcine
model and demonstrated that high negative surface charge plays
a critical role in the causation of this serious adverse reaction
associated with several liposomal nanopharmaceuticals.[372]
However, using polymer NPs, Mayer et al. showed that positive
surface charge induced activation of complement too.[388]
Misra et al. undertook a study to determine the effects of var-
ious NP characteristics (size, surface charge, molecular chem-
istry, and molecular weight of coating agents) on complement
activation using carbon spherical NPs. Their study showed that
the presence of a highly positive surface charge enhanced com-
plement activation.[389] Methoxy polyethylene glycol grafted li-
posomes are known to evoke immediate non-IgE mediated hy-
persensitivity reactions. The complement activation is thought
to be due to the presence of anionic phosphate-oxygen moiety
of the PEGylated phospholipid.[390] Interestingly, Moghimi et al.
showed that methylation of this phosphate oxygen moiety pre-
vents PEGylated liposome mediated complement activation.
6.4.4. Polydispersity
NP aggregates are known to induce complement activation. In a
study carried out by Mayer et al. to investigate the effect of size
and surface charge of the NPs on complement activation, induc-
tion of coagulation and hemolysis and activation of granulocytes
and platelets, it was shown that positive charge induced forma-
tion of NP aggregates and complement activation.[388] A simi-
lar observation was made in a recent study undertaken by Fülöp
et al. to study the role of iron core composition and particle sur-
face coating in six different commercially available superparam-
agnetic iron oxide NPs. This revealed that Sinerem is a strong
activator of complement. NP tracking analysis of the particles
showed that Sinerem displayed a multimodal size distribution
including a significant fraction of aggregates strengthening the
supposition that NP aggregates can lead to complement activa-
tion and CARPA.[391]
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6.4.5. Surface Characteristics/Modifications
Surface characteristics, both the intrinsic chemical composition
of the nanomaterial and any introduced modifications (“func-
tionalized”) play a pivotal role in complement activation. Of the
intrinsic chemical structures that are well known to induce com-
plement activation are the repetitive sequences and high sur-
face density of amino and hydroxyl moieties. Amino and hy-
droxyl groups are capable of directly activating and accelerating
AP.[392,393]
A widely used strategy to reduce NP clearance from circula-
tion by the RES is to decorate the particle surface with certain
molecules such as PEG, dextran or other polymeric coatings.
This strategy has proved effective in clinical pharmacology in
that this modification has significantly improved the pharma-
cokinetic properties including prolonged circulation time of a
number of pharmacological agents.[394–401] However, published
reports also suggest that there is a small risk that this process may
induce complement activation which in turn may lead to anaphy-
lactic reaction.[401–404] Both PEG and dextran have been reported
to cause CARPA. So much so that, several dextran-coated SPION
preparations (Sinerem, Combidex, and Ferridex) that have been
used in imaging as contrast medium were withdrawn from the
market. For this reason, dextran-coated NPs have come under in-
tense research scrutiny in recent years.
6.4.6. Dextran-Coated Nanoparticles
Dextran is a polysaccharide and as such it can activate the com-
plement system via the LP.[363] However, it can also trigger the
complement system in human blood through the AP.[405] It
should be noted that the potential to induce complement acti-
vation varies significantly depending on the chemical composi-
tion of the dextran compound used. In order to explore the roles
of iron core composition and particle surface coating in SPION-
induced CARPA, Fulop et al. measured complement activation
by six different SPIONs in a human serum that is known to
react to NPs with strong complement activation. Interestingly,
only the carboxymethyldextran-coated (ferucarbotran, Resosvist)
and dextran-coated (ferumoxtran-10, Sinerem) SPIONs caused
significant complement activation, while the citric acid, phos-
phatidylcholine, starch and chitosan-coated SPIONs had no such
effect.[391]
In addition to its composition, the configuration of the dex-
tran layer also plays an important role in complement activation.
Bertholon et al. investigated the influence of surface morphology,
length, and type of polysaccharide on complement activation by
measuring the degree of conversion of C3 into C3b in serum in-
cubated with NPs. Their study showed that the complement acti-
vation induced by dextran-coated NPs increased with the size of
dextran bound in “loops” compared to that of “brush” configu-
ration. The authors suggested that the observed difference could
be explained by an increasing steric repulsive effect of the brush,
inducing poor accessibility to OH groups.[406]
There appears to be a species difference in the mechanism of
complement activation caused by dextran-coated SPION. Banda
et al. carried out a study to investigate the mechanisms of com-
plement activation in human and mice using superparamagnetic
iron oxide nanowires (SPIONW) showed that the complement
activation in mice was mediated via the LP while direct enhance-
ment of the AP was the main mode of activation in human
serum.[363]
In order to minimize dextran mediated complement activa-
tion, Unterweger and colleagues made modifications to the com-
position of the dextran coating. Magnetic NPs were coated with a
formulation containing low molecular weight (10 kDa) unmodi-
fied dextran, mannitol and citrate. Hemocompatibility (effects on
red cells, leucocytes, platelets, coagulation, and complement sys-
tem) of these particles (named SPIONdex) were studied in vitro.
In addition, the researchers conducted in vivo experiments using
domestic pigs to investigate its potential to induce CARPA follow-
ing i.v. infusion. The researchers report that SPIONdex is highly
hemocompatible with minimal adverse effects on blood cells, co-
agulation, and complement system. Significantly, SPIONdex par-
ticles did not induce CARPA even at high concentration.[407]
6.4.7. Polyethylene Glycol Coated Nanoparticles
PEG, a highly hydrophilic polymer, is the most widely used
stealth polymer for NCs in order to reduce clearance by the RES
thus extending circulation time and improving drug efficacy.[408]
However, polyethylene glycol coated (“PEGylated”) pharmaceu-
tical formulations such as Doxil (PEGylated liposomal dox-
orubicin) have been associated with severe hypersensitivity
reactions.[409]
Several reports indicate that antibodies to PEG play a direct
role in inducing complement activation via antibody-mediated
classic pathway.[408,410] Anti-PEG antibodies have been shown
to be present in the blood of patients who have been ex-
posed to PEGylated pharmaceuticals[411] and also in unexposed
population.[412–414] In addition to inducing hypersensitivity reac-
tions, these antibodies also cause accelerated clearance of PEGy-
lated drugs from blood leading to reduced clinical efficacy.[414,415]
Although activation via the classic pathway appears to play a
major role in PEGylated NCs induced complement activation,
other pathways (alternate and lectin) may also play a role. Hamad
et al. studied the interaction between PEGylated SWCNTs and the
complement system. They showed that PEGylated SWCNTs acti-
vated complement and induced production of C4 without any in-
crease in alternate pathway activation. Furthermore, SWCNT in-
duced complement activation was unaffected by depletion of C1q
with anti-C1q antibody but not antimannan-binding lectin serine
protease (MASP) 2 antibodies. The authors suggested a possible
LP in PEGylated SWCNTs induced complement activation.[416]
6.5. Nanoparticle-Induced Complement Activation: The
Challenge for Brain Drug Delivery
Despite the tremendous advances made over the last few years
in understanding the pathogenesis of NP-induced complement
activation and the associated clinical syndromes, hitherto no reli-
able solutions to overcome this potentially serious complication
of NCs have been discovered. Hence, development of effective
measures to minimize or eliminate this adverse reaction will be
an essential prerequisite for successful NP-based drug delivery.
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Although it remains to be determined the complement activation
by conventional cell penetrating peptides such as RVG-29, it has
been suggested that the use of ApoA-I may be advantageous in
designing of brain targeting NPs.[417] This is because ApoA-I in-
teracts with an activation-dependent conformer(s) of the C9 com-
ponent of the C5b-9, which inhibits C9 polymerization, hence
minimizing the risk of complement activation.[418–365] On the
other hand, polystyrene NPs form a protein corona in serum with
ApoA-I being one of the dominant adsorbed proteins.[420] How-
ever, this does not prevent complement activation by polystyrene
NPs in human serum.[421] Therefore, further investigations are
required to examine the suitability of using ApoA-I as a brain
targeting ligand for NPs and avoiding complement activation by
these NPs.
7. Cytotoxicity, Hemolysis, and Immunogenicity
When NPs/NCs are employed for drug delivery to the brain, these
NPs/NCs should be nontoxic to bystanding cells as well as neu-
rons, in particular when the cargo is noncytotoxic agent. Further-
more, when brain targeting NPs/NCs are administered i.v., these
should not cause hemolysis as loss of red blood cells (RBCs) may
lead to anemia. Finally, brain targeting NPs/NCs should be non-
inflammatory and nonimmunogenic. Otherwise, they may be
cleared rapidly from the blood stream and brain by macrophages;
or the NPs/NCs may activate brain microglia causing undesired
injuries to brain cells, or worsen the damages to neurons in dis-
eased brains. In the following sections, the toxicity of NPs is dis-
cussed as well as their immunogenicity and hemolysis.
7.1. Cytotoxicity
It is quite critical that NP formulations are assessed and con-
firmed to be safe in terms of their nontoxicity to cells, lack of
(or negligible) capacity to provoke unwanted immunological re-
actions, and nonlytic effects on the RBCs. The NP formulations
targeting the CNS are tested experimentally using neuronal cell
lines and primary neurons in vitro to assess their cytotoxicity
and immunogenicity.[22] These neuronal cells are very useful in
modeling various brain diseases through application to them of
a wide range of experimental agents under several different ex-
perimental conditions. As a result of their versatility, they are an
excellent tool in elucidating the cellular and molecular mecha-
nisms underlying CNS disorders and are, therefore, important
to the study of brain-targeting NPs. A battery of assays can be
used to assess the effects of a NP on cell (including neuronal)
viability (or its induction of cell death), usually by quantifying
treatment-induced changes to the levels or activities of a spe-
cific enzyme or a group of enzymes, or residual cellular energy
content as indicated by intracellular levels of adenosine triphos-
phate (ATP),[422–424] or residual levels of some other intermediate
for metabolic activity. These assays are commonly based on ab-
sorbance, fluorescence or luminescence readouts. Some of them
are destructive (lytic) and are, therefore, only useful for endpoint
determinations, while some are nondestructive and, therefore,
able to assess changes in either endpoint or kinetic mode (time
course), thus having an additional advantage of allowing the cells
assayed for viability to be used for other assays, if required. Exam-
ples include the absorbance-based tetrazolium reduction (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide [MTT])
assay (one of the most commonly used) or any of its more recent
improved versions (MTS, XTT, WST-1); the alamarBlue assay
(fluorescence- or absorbance-based), and the bioluminescence-
based ATP assays.[423,425,426]
While the underlying assumption in using these assays is that
the extent of the changes to the surrogate parameters being cap-
tured correlates well with metabolic activity and cell viability, each
assay has caveats associated with it that must be taken into con-
sideration while deciding which one(s) to employ. One of the
major challenges is the potential interaction between a test sub-
stance and the assay reagents or systems, which can lead to false
positives and, therefore, has to be properly controlled for in the
design of viability testing experiments. In this context, it should
be noted that some NPs have demonstrated, or are suspected to
have, real potential for interacting with cell viability reagents and
this reality or possibility should be considered when assessing cy-
totoxicity of NPs.[427–430] A useful and recommended approach is
to use at least two cell viability assays that are based on different
readouts to assess the effects of NPs on cell viability. Such assays
could be designed to run as separate or multiplex systems. There
should also be appropriate controls to assess the potential interac-
tions between NPs and the assay reagent or system in the absence
of cells. Although for a given test substance differences in its tox-
icity profiles obtained from separate assays might be related to its
mechanism(s) of induction of cytotoxicity, such differences could
also be an indicator of unwanted interactions or artefacts inher-
ent in one assay compared to the other(s) and could, as a result,
guide the subsequent choice of assays as well as results interpre-
tation. It is also good practice to assess the neurotoxicity of a NP
using a range of neuronal cell lines and primary neurones.
Table 7 summarizes the cytotoxicity of recent brain-targeting
NP formulations evaluated using the MTT assay.[431] It can be
seen that inclusion of the transactivator of transcription (TAT)
peptide in the NPs significantly increased their cytotoxicity. Fur-
thermore, PLGA NPs conjugated with lactoferrin did not show
cytotoxicity at concentrations as high as 10 000 µg mL−1, while
conjugating PLGA NPs with TAT peptide reduced safe concen-
tration down to 20 µg mL−1. These observations indicate certain
brain-targeting ligands may make NPs less cytotoxic compared
to other brain-targeting ligands. Interestingly, targeted exosomes
showed a safe concentration limit of 20 µg mL−1, which is
lower than for lactoferrin-PLGA, RVG-PLGA, and solid lipid
NPs. Also, while RVG-PLGA NPs did not show cell toxicity at a
concentration of 1000 µg mL−1, the noncytotoxic concentration
for RVG-trimethylated chitosan NPs was 100 µg mL−1. There-
fore, the NP core plays a crucial role in the cytotoxicity of the
decorated NP with brain-targeting ligand. As expected, loading
NPs with cytotoxic chemicals increased the toxicity of the NP
formulation.
Lactate dehydrogenase (LDH) is an enzyme that is released
as a result of cell membrane damage when cells are exposed to
NPs. In the LDH assay the amounts of released LDH are quanti-
fied and are proportional to the extent of (necrotic) cell death.[456]
Table 8 presents a summary of typical NP formulations that were
evaluated for cytotoxicity using the LDH assay. These NPs were
formulated or considered for drug delivery to the brain. It can be
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Table 7. The cytotoxicity of NPs designed for brain delivery toward cell lines evaluated by the MTT test.
NP formulation 90% Viability control
NPs [µg mL−1]
Drug 90% viability loaded
NPs [µg mL−1]
Cell line Size [nm] Ref.
Lactoferrin-PLGA 10 000 Huperzine A 100 16HBE 153.2 ± 13.7 [432]
SLNP (cetyl palmitate) 1500 Functionalized with Apo E 1500 hCMEC/D3 192 ± 13 [433]
PLGA-Tf 1000 Oxytocin 1000 RAW 246.7 197.7–278.3 [434]








300 (no irradiation) ALTSICI 80 ± 1 [435]
RVG-trimethylated chitosan NPs 100 siRNA 100 Neuro-2a 135 ± 7 [436]
PLGA 100 Diazepam 50 Green monkey kidney
epithelial cells
190 ± 0.5 [437]
Mn-LDH
a)
100 siRNA 21.6 Neura2a 125 [438]
Magnetic poly
(d,l-lactide-co-glycolide) lipid
80 Glutathione 80 bEnd.3 102.0 ± 0.7 [439]
Poly (butylcyanoacrylate) 60 Cisplatin 12.5 A172 451.2 ± 11.1 [440]
SLNP (glyceryl distearate) 40 Asiatic acid 18 SVG P12 human fetal
glial
94–141 [441]




20 Glutathione <20 bEnd.3 131.8 ± 11.2 [439]
Targeted exosomes 20 Doxorubicin <20
b)
BT-474 30–100 [443]
PLGA 2.5 Lamotrigine 1.25 Neuro-2a 184.6 [444]
Liposomes ND 1,9-Pyrazoloanthrone 100 SH-SY5Y 112.33 ± 0.84 [445]
gH625-Fe3O4 magnetic NPs
c)




104.0 ± 4.0 [446]
a)
Manganese based layered double hydroxide nanoparticles
b)
At 20 µg mL−1 the toxicity of exosomes was about 20% (cell viability 80%) similar to free Doxorubicin
c)
gH625
(H2N-HGLASTLTRWAHYNALIRAFGGG-CONH2)[447] a BBB crossing peptide
d)
Human brain microvascular endothelial cells (HBMEC).
Table 8. The cytotoxicity of NPs designed for brain delivery toward cell lines evaluated by the Lactate dehydrogenase (LDH) assay.
NP formulation 90% Viability control
NPs [µg mL−1]
Drug 90% viability for
loaded NPs [µg
mL−1]
Cell line Size [nm] Ref.
SLNP (DSPE) 1850 Functionalized with Apo
E3+resveratrol
3700 hCMEC/D3 167.8 ± 19.9 [448]
SLNP (cetyl palmitate) 1500 Functionalized with
ApoE3
1500 hCMEC/D3 192 ± 13 [433]








33 NA NA Human neutrophils 195 [450]
zero-valent iron 20 𝛼-Synuclein amyloid <20 SH-SY5Y 83.88
a) [451]
Single-walled nanotubes 1 None None PC-12 0.84 ×
700–1000
[452]
Transferrin-SLNP (cetyl palmitate) ND Quercetin 2400 hCMEC/D3 200 [453]
Nickel oxide ND NA 10 SH-SY5Y 89.73 ± 5.98 [454]
Peptide nanofibers ND siRNA 11 hCMEC/D3 50 × 297 [455]
a)
This is hydrodynamic diameter, the actual NP diameter was 30 nm.
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seen that SWNTs present significant toxicity toward cells com-
pared to the other formulations.
Cell toxicity induced by NCs or NPs could lead to a range of
death outcomes, including apoptosis (programmed cell death)
and necrosis. Knowledge of the potential of NCs or NPs to in-
duce such death paradigms is, therefore, important, for exam-
ple, in the case of NPs or NCs delivering noncytotoxic therapeu-
tic agents such as nerve growth factor or siRNA to downregulate
the BACE1 gene.[23,24]Although apoptosis as a genetically pro-
grammed process is involved in organismal development and
the maintenance of homeostasis, various external triggers are
also known to initiate it. Apoptosis could be mediated through
an intrinsic (mitochondrially mediated) pathway or an extrinsic
pathway (via cell-surface death receptors), and, depending on the
nature of the toxic insult, could occur early or late in the death
process.[457] In early apoptosis, the cell membrane is intact, while
in late apoptosis the cell membrane is permeable. Here we pro-
vide a few recent examples of the induction of apoptosis by brain-
targeting NPs. Dual functionalized (transferrin and penetratin)
liposomes induced 10% apoptosis in bEnd.3 cells after 2 h of
incubation,[458] while poly (butylcyanoacrylate) NPs induced less
than 1% apoptosis in A172 cancer cell line.[440] Loading these
NPs with anticancer drugs significantly increased their apoptotic
effects. On the other hand, synthetic silicone dioxide NPs with-
out any drug load induced apoptosis from 50 µg mL−1 concen-
trations and above in LN229 cell lines,[459] whereas mesoporous
silica NPs did not induce significant apoptosis in A127 cells at
374 µg mL−1.[460] Interestingly, SPIONs did not induce apopto-
sis at 50 µg mL−1 in PC12 cells, but they promoted apoptosis at
concentrations in the range of 60–200 µg mL−1.[461]
Necrosis is cell death characterized by cytoplasmic swelling
and cells rounding up, bursting and collapsing, spilling out their
intracellular content.[462,463] Leakage of cellular content into the
extracellular medium represents a “danger signal” as it could pro-
voke inflammation.[464] Ag NPs caused necrosis at concentration
in the region of 50 µg mL−1 in L-929 fibroblast cells, with 10 nm
NPs being more toxic than 200 nm NPs, causing more than 50%
necrosis after 24 h incubation.[25] Chiani et al. showed that blank
PBCA NPs caused less than 1% necrosis, while loading these
NPs with cisplatin did not increase necrosis in A172 brain cancer
cell lines.[440] On the other hand, biotinylated PAMAM G3 den-
drimers substituted with the cyclooxygenase-2 (COX-2) inhibitor
celecoxib and peroxisome proliferator-activated receptor agonist
(Fmoc-l-Leucine) caused late apoptosis (which was considered
necrosis) in HaCaT cells at 4× 10−6 m concentration.[465] Interest-
ingly, silica-coated iron oxide NPs did not cause necrosis (or late
apoptosis) at concentrations as high as 200 µg mL−1 in SH-SY5Y
cells.[466]
7.2. Hemolysis
The hemolysis test is conducted to evaluate the effects of NP
formulations on the RBCs. Joshy et al. evaluated hemolysis of
alginate–stearic acid/PEG NPs (ASNPs) on the RBCs. They re-
ported no hemolysis or aggregation was observed in white blood
cells, RBC and platelets.[27] Ishak et al. tested lipid polymer hybrid
NPs and gold NPs for hemolysis using rat blood (RBC) and then
calculated percentage hemolysis by using the equation below.
They reported all formulations were below permissible hemol-
ysis threshold (5%) at 1 mg mL−1, whereas at 2 mg mL−1 the
hemolysis was higher than the threshold[467]
Hemolysis (%) = ODt − ODnc
ODpc − ODnc
× 100 (1)
where ODt, ODnc, and ODpc are the optical densities of the
test sample, the negative control, and the positive control, respec-
tively. Hemolytic activity of brain targeting NPs/NCs have been
investigated.[458,468–476] Among NPs or NCs for brain drug de-
livery, amphiphilic peptides (C16-W-I-L-A2-G3-K9-TAT) showed
hemolysis at low concentrations such as 25 µg mL−1,[469] while
PAMAM G4 dendrimer (G4) induced less than 5% hemolysis at
a concentration of 1280 µg mL−1.[474]
7.3. Immunogenicity
The immunogenicity of NPs is well known.[26] Judge et al. de-
veloped PEGylated liposomes and showed that the in vivo ef-
ficacy and safety of these systems could be severely compro-
mised following repeated administration. This phenomenon was
characterized by a loss of disease site targeting, enhanced clear-
ance from the blood, and acute hypersensitivity. These outcomes
were attributed to a surprisingly robust, long-lived antibody re-
sponse generated against PEG that resulted from the strong ad-
juvant effect of the payload (plasmid in this case).[477] Therefore,
investigators evaluated immunogenicity of NP formulations for
drug delivery to the brain.[84,434,478] Previous work showed that
RVG-surface decorated liposomes and exosomes slightly induced
the release of pro-inflammatory cytokines (TNF-𝛼, IFN- 𝛾 , IL-
1𝛽, IL-6) upon multiple injections to animal models.[23,478] How-
ever, PLGA and BSA NPs decorated with RVG or Tf did not
present immunogenicity.[434] Tf is a single chain 80 kDa pro-
tein that facilitates the movement of iron between the blood
and brain. These NPs contained oxytocin with sizes in the
range of 100–278 nm, with slight negative charges. The pos-
sibility of the NP formulations to induce an immunogenic re-
action was assessed by measuring the amount of nitrite re-
leased by dendritic cells in the presence of NPs. Oxidation of
nitric oxide yields nitrite, and nitric oxide release is an impor-
tant marker for the innate immune response.[479] Neither PLGA
nor BSA NPs decorated with RVG produced significant amounts
of nitric oxide. The same observation was made for PLGA and
BSA NPs decorated with Tf. This study favored using RVG
targeting ligands, as these NPs were half the size of Tf deco-
rated NPs (RVG-conjugated BSA (100.1 nm), Tf-conjugated BSA
(196.3 nm), Tf-conjugated PLGA (191.7 nm), RVG-conjugated
PLGA (201.2 nm)).[436] On the other hand, Arranz-Gibert et al.
found that the all L-versions of THR (THRPPMWSPVWP) and
HAI (HAIYPRH) peptides were immunogenic.[480] The im-
munogenicity of these peptides were evaluated by several admin-
istrations of the peptide by i.p. injection into mice, and eval-
uation of the antibody in the blood by ELISA. It was demon-
strated that two retro-D-peptides (H2N-HRPYIAH-CONH2 and
H2N-PWVPSWMPPRHT-CONH2) were protease-resistant and
preserved the original BBB shuttle activity of the parent pep-
tide, but were much less immunogenic than the parent peptides.
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As explained in the above, there are established in vivo and in
vitro methods to evaluate the immunogenicity of NPs.[22] In ad-
dition, Rudra et al. showed that using adoptive transfer experi-
ments and T cell knockout models, it was possible to find anti-
body responses against self-assembling peptides. Consequently,
by deleting amino acid regions in the peptides recognized by
T cells, immunogenicity was significantly diminished for self-
assembled nanofibers.[481] This technique could be applied to
identify effective brain targeting ligands with reduced immuno-
genicity.
Aptamers are small single stranded RNA or DNA molecules
that bind to their target through shape recognition, simi-
lar to that of conventional antibodies. Aptamers have been
developed as brain targeting ligands. Low immunogenic-
ity is one of the main advantages of aptamers.[482] For ex-
ample, Pegaptanib sodium drug substance is a pegylated
anti-VEGF aptamer;[483] for the treatment of choroidal neo-
vascularization secondary to age-related macular degenera-
tion, which was well tolerated in clinical trials (phase II,[484]
phase III[485]) after multiple intravitreal injections. Although
Macugen (pegaptanib) was withdrawn from the European
market by the European Medicines Agency in 2011 (https:
//www.ema.europa.eu/en/documents/withdrawal-report/
withdrawal-assessment-report-macugen_en.pdf ), the deci-
sion was not based on immunogenicity of the product. In fact,
the report states that only 4 patients out of 131 showed an
IgG antibody response to non-PEGylated pegaptanib following
multiple injections over one year of the treatment. However, it
should be noted that there are individuals positive for antinu-
clear antibodies. The report adds that 5/100 individuals were
positive for antipegaptanib IgG, and 13/100 were positive for
anti-non-PEGylated pegaptanib IgG, but the numbers do not
appear significant.
The identification of aptamers is achieved typically by an in
vitro selection process termed systematic evolution of ligands by
exponential enrichment (SELEX).[486] This method was applied
to identify an aptamer that specifically targets the extracellular
domain of the mouse TfR.[487] Despite being a challenging pro-
cess, aptamers are making their ways into neuroscience.[488,489]
To make this process more efficient, Cheng et al. developed
an in vivo evolution protocol to identify aptamers that home to
the brain after injection to peripheral tissues. This method in-
volved the injection of the aptamers intravenously, then harvest-
ing mouse brain, extracting the aptamers, purification, amplifica-
tion and re-injecting into subsequent animals.[490] The cycle was
carried out for 22 rounds. Applying this method led to identifying
an efficient aptamer with 71 nucleotides
(A15: 5′GGG AGG ACG AUG CGG CGU AUU GCG CGA
GGA UUA UCC GCU CAU CGU UGU UGU UGU GCA GAC
GAC UCG CCC GA3′) with the ability to target the brain. Al-
though A15 showed enhanced accumulation in the brain, most
of the i.v. injected aptamer was retained by the kidneys and liver.
Although immunological reactions were not measured in this
study, continuous testing of the aptamers in the mice suggests
nonimmunogenicity of these ligands.
Monaco et al.[491] conjugated the Gint4.T aptamer (5′UGU
CGU GGG GCA UCG AGU AAA UGC AAU UCG ACA3′)[492]
to the surface of PLGA-b-PEG-COOH NPs to yield PLGA-
b-PEG-Gint4 NPs with the size of 52 nm. The Gint4.T ap-
tamer not only can cross the BBB, but also can target the 𝛽
form of platelet-derived growth factor receptors on glioblastoma
cells.[492] PLGA-b-PEG-Gint4 appeared in the brain of mice bear-
ing U87MG orthotopic xenografts following i.v. injection.[491] Uti-
lizing scrambled aptamer, the NPs did not accumulate in the
glioblastoma.[491] The immunogenicity of the NPs was not evalu-
ated. In another study but with the same brain disease, Tang et al.
labeled quantum dots with an aptamer (A32: 5′GCA ATG GTA
CGG TAC TTC CTG AAT GTT GTT TTT TCT CTT TTC TAT
AGT ACA AAA GTG CAC GCT ACT TTG CTA A3′), which binds
to the epidermal growth factor receptor variant III (EGFRvIII)
particularly expressed on the surface of glioma cells.[493] These
labeled quantum dots (QD-Apt) accumulated in the glioblastoma
cells in the brains of mice bearing U87-EGFRvIII tumors. Al-
though QD-Apt NPs had diameters of about 20 nm, the accumu-
lation of these NPs in the tumors was not because of the EPR.
The QD-Apt NPs did not induce inflammation in the brain, heart,
liver, spleen, lungs, or kidneys after multiple injections over 28
days with 7-day gaps between injections.[493]
In conclusion, aptamers are promising brain targeting lig-
ands. This is because, the nonimmunogenicity profiles have
been shown both in vivo and in clinical trials (Pegaptanib) for ap-
tamers. While aptamers are susceptible to degradation by the nu-
cleases in the serum, these may be overcome by altering the sugar
position in the aptamer sequence and using oligonucleotides
containing modified nucleotides in the aptamer sequence.[494]
More importantly, aptamers can self-assemble into NPs with
the sizes of 50 or 59 nm (depending on loaded drug), simply by
mixing equimolar amounts of complementary
oligonucleotides.[495] Alternatively, aliphatic chains
((CH2CH2O)24)
[496] can be conjugated to aptamers to make
amphiphilic aptamers. These aptamers can self-assemble to
NPs with size of 68 ± 13 nm,[496] which makes them suitable
for brain drug delivery. Interestingly, cholesterol-conjugated
aptamers self-assembled to NPs of 120 nm,[497] which is in
agreement with the size of self-assembled NPs (150 nm) from
cholesterol-TAT amphiphilic peptides.[498] The latter NPs were
able to penetrate the BBB and suppress bacterial growth in
the brain. Therefore, cholesterol-conjugated aptamer NPs may
be able to deliver RNA interference to the brain.[497] It should
be noted that cholesterol-TAT self-assembled NPs induced
hemolysis at concentrations as low as 50 µg mL−1,[498] and this
is in agreement with observations in our experiments for RVG
based NPs (unpublished data). Aptamers, however, have not
been reported to promote hemolysis. Hence, if brain targeting
aptamers are employed in the self-assembled NCs, then these
may be employed as drug delivery to the brain with a better
safety profile compared to other NP based drug delivery systems.
7.4. The Interaction between Microglia and Nanoparticles
Microglia are the resident immune cells of the brain, which are
primarily involved in surveillance, phagocytosis, and production
of cytokines such as Tumour necrosis alpha (TNF-𝛼) and trophic
factors such as brain-derived neurotrophic factor (an important
role in neuronal survival and growth). Microglia respond rapidly
to alterations in the brain homeostasis. Therefore, microglia can
respond to the presence of NPs in the brain. The uptake of NPs
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by microglia can be as early as 3 h after the exposure of the cells to
NPs.[499] Activated microglia internalize more NPs compared to
resting microglia.[500] Polymeric NPs in the brain were internal-
ized by microglia depending on the size and surface charge.[501]
In addition, gold NPs were internalized by microglia, which ac-
tivated these cells.[502] The surface chemistry of the NPs plays a
major role in the activation of microglia.[503] For example, sur-
face coating of gold NPs with PEG did not activate microglia,
while coating the NPs with cetyltrimethylammonium bromide
activated microglia.[503] Similarly, silver NPs (50 nm diameter)
were internalized by microglia, and microglia dissolved these
NPs within themselves. Interestingly, the silver NPs upregulated
the expression of cystathionine-𝛾-lyase, which produces hydro-
gen sulfide (H2S) in the microglia. The increased levels of H2S re-
duced the release of TNF-𝛼, when the microglia were challenged
with lipopolysaccharide.[504] On the other hand, NPs can stimu-
late the microglia and as a result damage the neurons. These in-
clude SiO2-NPs, TiO2-NPs, Fe3O4-NPs, and hydroxyapatite-NPs.
The interaction of these NPs with microglia released TNF-𝛼, IL-
1B, and IL-6.[505] Furthermore, neuroinflammation is associated
with impaired microglia functions, and these cells have increased
uptake of dendrimer NPs. This shows that in diseased brain
the clearance of NPs by microglia could increase compared with
healthy brain.[506] As well as undesired uptake of NPs by mi-
croglia, NPs may be engineered to specifically target microglia.
For example, curcumin-loaded chitosan–bovine serum albumin
NPs targeted microglia and activated these cells to accelerate the
phagocytosis of A𝛽 peptide.[507] As another example, Choi et al.
showed that surface decoration of ceria–zirconia NPs (18 nm di-
ameter) with microglia specific-antibody (CD11b) allowed the up-
take of these NPs by microglia and reducing the release of IL-1𝛽
and IL-6 due to the presence of reactive oxygen species.[508] Simi-
larly, inclusion of mannose in Pluronic-F127 polymer and tannic
acid (TA) based NPs increased the uptake of these NPs by po-
larized microglia. As polarized microglia overexpress mannose
receptors.[509]
In conclusion, in the design of NPs for brain delivery, it should
be noted that these NPs may not only be internalized by mi-
croglia, which leads to reduced efficacy of NPs, but also cause the
activation of microglia, which could result in neuronal injuries.
Therefore, NPs will be picked up by microglia, one way or an-
other, this is their job. However, ingredients may be included
in the NPs such that microglia will not be polarized to a pro-
inflammatory state.
8. Conclusion
This review article highlights changes in the BBB related to ag-
ing and diseases, and how these affect our ability to target the
brain using NPs or NCs. Although aging and brain diseases in-
crease the BBB permeability, the deposition of blood proteins in
the BL can repair the BBB barrier functionality to some degrees.
Aging changes the BBB morphology, permeability, and function-
ality. The expression of important receptors such as that for in-
sulin or transporters such as P-gp decreases. This is also applica-
ble to the BBB in diseased states, with the receptor profile of the
BBB changing. In AD the BBB permeability increases, however,
the diffusion of NPs into the brain may be hindered due to A𝛽 de-
position around brain microvessels. In MS, the BBB permeabil-
ity increases, yet, NPs in the size of 20–40 nm find difficulties to
cross the BBB in patients. The BBB integrity remains relatively
intact in PD, hence, direct injections to the brain have been em-
ployed in clinical trials. On the other hand, the BBB permeability
increases in brain tumors. Both targeted and nontargeted NPs
in the size range of 3.25–400 nm have been employed in clinical
trials, although the presence of brain targeting ligands improves
drug delivery to the brain. Similarly, BBB permeability increases
following ischemic stroke both in humans and animal models.
Therefore, nontargeted NPs would cross the compromised BBB,
while brain targeted NPs would have more efficacy. Administer-
ing NPs i.v. could result in complement activation, cytotoxicity
and hemolysis, and induction of the release of pro-inflammatory
cytokines (TNF-𝛼, IFN- 𝛾 , IL-1𝛽, IL-6). The activation of the com-
plement system leads to the generation and deposition of op-
sonins such as C3b on the surface of the NPs (opsonization).
The opsonized NPs are rapidly engulfed by macrophages, which
leads to reduction of the nanoparticle therapeutic efficacy. NPs
could cause death, apoptosis or necrosis of neurons. This is im-
portant when NPs or NCs are employed to deliver noncytotoxic
therapeutic agents to the brain such as nerve growth factor. Brain
targeting NPs could cause hemolysis, in particular amphiphilic
peptides. If hemolysis is significant, then this could lead to ane-
mia. Furthermore, the rupture of red blood cells may affect NP
opsonization, and influence distribution and delivery to the
intended target sites, or promote uptake and clearance by
macrophages. In vitro BBB models aim to inform the potential
for pharmaceutical drug candidates to cross the BBB and reach
the neurons or brain extracellular environment. Although cur-
rent in vitro methods are far from a perfect facsimile of the BBB
in vivo, good correlation between in vitro and in vivo drug per-
meability has been reported.
We have described the biological and physical background to
many of these current challenges and opportunities for the de-
velopment of new therapeutic options to treat diseased and dam-
aged brains. Navigating the opportunities provided by physiolog-
ical changes in the BBB and exploiting the latest models must be
done while simultaneously avoiding the challenges of comple-
ment activation, immunogenicity, cytotoxicity and other toxicity.
The prize for navigating this path could be a revolution in thera-
pies targeting the brain.
9. Future Directions
The physiological and pathological changes in the BBB should be
taken into account for drug delivery to the brain using NPs. This
encompasses changes in the receptor profile of the BBB and mod-
ifications in the BL, which makes diffusion of NPs difficult in the
brain parenchyma. Therefore, brain targeting ligands should be
carefully selected to ensure efficient delivery of the NPs across the
BBB. It is possible that enzyme responsive NPs would provide the
benefit of releasing the drug content in the brain parenchyma fa-
cilitating fast diffusion of small active therapeutic agents in the
brain parenchyma. Furthermore, enzyme responsive NPs may
prevent activation of brain-resident macrophages, because rapid
disintegration before recognition by microglia. Certainly, nonin-
vasive brain-targeting NPs would be the way forward. This is not
only to minimize further damages to the diseased brain, but also
to reduce the costs of treatment by eliminating the need for a
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surgeon to make a hole in the skull for injecting the active in-
gredient/NPs into the brain. The scalability and reproducibility
of NP production should be taken into consideration. Simpler
procedures would not only reduce the complexity of the manu-
facturing process of NPs, but also improve batch-to-batch consis-
tency, which is favored by regulatory authorities. Certainly, there
is a requirement for the development of safe and nonthrombo-
genic NPs that target the blood clots in the brain vessels that un-
derlie the brain ischemic stroke. Rapid responding NPs will be
favored to re-establish the blood flow in the brain as quickly as
possible following the stroke. In this regard, enzyme-inhibiting
NPs would also be useful during the early hours of the stroke.
This is because, following an ischemic stroke, the levels of de-
generative enzymes such as MMP-9 increase in the brain, which
are correlated with poor disability outcomes.
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